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A B S T R A C T
Background
TheWorld Health Organization recommends routine vitamin A supplementation during pregnancy or lactation in areas with endemic
vitamin A deficiency (where night blindness occurs), based on the expectation that supplementation will improvematernal and newborn
outcomes including mortality, morbidity and prevention of anaemia or infection.
Objectives
To review the effects of supplementation of vitamin A, or one of its derivatives, during pregnancy, alone or in combination with other
vitamins and micronutrients, on maternal and newborn clinical outcomes.
Search strategy
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (15 July 2010).
Selection criteria
All randomised or quasi-randomised trials, including cluster-randomised trials, evaluating the effect of vitamin A supplementation in
pregnant women.
Data collection and analysis
Two review authors independently assessed all studies for inclusion and resolved any disagreement through discussion with a third
person. We used pre-prepared data extraction sheets.
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Main results
We examined 88 reports of 31 trials, published between 1931 and 2010, for inclusion in this review. We included 16 trials, excluded
14, and one is awaiting assessment.
Overall when trial results are pooled, Vitamin A supplementation does not affect the risk of maternal mortality (risk ratio (RR) 0.78,
95% confidence interval (CI) 0.55 to 1.10, 3 studies, Nepal, Ghana,UK ), perinatal mortality, neonatal mortality, stillbirth, neonatal
anaemia, preterm birth or the risk of having a low birthweight baby. Vitamin A supplementation reduces the risk of maternal night
blindness (risk ratio (RR) 0.70, 95% CI 0.60 to 0.82, 1 trial Nepal). In vitamin A deficient populations and HIV-positive women,
vitamin A supplementation reduces maternal anaemia (risk ratio (RR) 0.64, 95% confidence interval (CI) 0.43 to 0.94, 3 trials,
Indonesia, Nepal,Tanzania ). There is evidence that vitamin A supplements may reduce maternal clinical infection (RR 0.37, 95% CI
0.18 to 0.77, 3 trials, South Africa, Nepal and UK).
In HIV-positive women vitamin A supplementation given with other micronutrients was associated with fewer low birthweight babies
(< 2.5 kg) in the supplemented group in one study (RR 0.67, CI 0.47 to 0.96).
Authors’ conclusions
The pooled results of two large trials in Nepal and Ghana (with almost 95,000 women) do not currently suggest a role for antenatal
vitamin A supplementation to reduce maternal or perinatal mortality. However the populations studied were probably different with
regard to baseline vitamin A status and there were problems with follow-up of women. There is good evidence that antenatal vitamin
A supplementation reduces maternal anaemia for women who live in areas where vitamin A deficiency is common or who are HIV-
positive. In addition the available evidence suggests a reduction in maternal infection, but these data are not of a high quality.
P L A I N L A N G U A G E S U M M A R Y
Vitamin A supplementation during pregnancy for maternal and newborn health outcomes
Vitamin A is a fat-soluble vitamin derived from the retinoids retinal and retinoic acid, found in liver, kidney, eggs, and dairy produce.
Carotenoids are converted to vitamin A in the liver, where vitamin A is stored; beta-carotene is found in dark or yellow vegetables and
carrots. Low dietary fat intake or intestinal infections may interfere with the absorption of vitamin A. Natural retinoids are required
for a wide range of biological processes including vision, immune function, bone metabolism and haematopoiesis. In pregnancy, extra
vitamin A may be required. Currently, the WHO and other international agencies recommend routine vitamin A supplementation
during pregnancy or at any time during lactation in areas with endemic vitamin A deficiency (where night blindness occurs).
The principal forms used as nutritional supplements are vitamin A palmitate (retinyl palmitate) and vitamin A acetate (retinyl acetate)
but carotenoids (most commonly beta-carotene) and retinoids (retinol, retinal, retinoic acid) can also be used as nutritional supplements.
Signs of vitamin A deficiency include night blindness, dryness of the conjunctiva and cornea and a diminished ability to fight infections,
especially respiratory and gastroenteric infections.
Findings of this review do not suggest a role for antenatal vitamin A supplementation to reduce maternal or perinatal mortality. There
is, however, good evidence that antenatal vitamin A supplementation reduces maternal anaemia in women who live in areas where
Vitamin A deficiency is common or who are HIV-positive. The available evidence suggests a reduction in maternal infection but these
data are not of a high quality and further trials would be needed to confirm or refute this.
We included 16 randomised trials where vitamin A was commenced pre-pregnancy or during pregnancy and in some cases continued
into the postnatal period. Seven trials were conducted in Africa, five in Indonesia and one each in India, Nepal, UK and USA. The
trials were conducted in populations considered to be vitamin A deficient except for the trials in the USA and UK.
Vitamin A supplementation did not reduce the risk of maternal mortality, perinatal and newborn mortality, stillbirth, preterm birth,
low birthweight or newborn anaemia. The risk of maternal anaemia, infection and night blindness was reduced. In one study, for
women who were HIV-positive, the addition of vitamin A to supplements of iron and folate did result in fewer low birthweight babies
(less than 2.5 kg at birth). The trials published so far did not report any side effects, adverse events or congenital malformations. The
dose of vitamin A given, in combination with additional micronutrients and the duration of supplementation differed in the trials and
varied between 5000 IU and 10,000 IU for daily doses, around 200,000 IU vitamin A for weekly supplementation and 200,000 IU
vitamin A at time of delivery.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin A for maternal and newborn mortality and morbidity
Patient or population: Pregnant women
Settings: Areas with endemic vitamin A deficiency (inadequate intake)/areas with adequate intake as defined by the WHO global database on vitamin A deficiency
Intervention: Vitamin A
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Vitamin A
Maternal mortality Low risk population1 RR 0.78
(0.55 to 1.1)
94373
(3 studies)
⊕⊕⊕⊕
high2,3
4 per 1000 3 per 1000
(2 to 4)
Medium risk population1
4 per 1000 3 per 1000
(2 to 4)
High risk population1
6 per 1000 5 per 1000
(3 to 6)
Perinatal mortality 55 per 1000 56 per 1000
(52 to 59)
RR 1.01
(0.95 to 1.07)
76176
(1 study)
⊕⊕⊕⊕
high2
Preterm birth Low risk population4 RR 0.77
(0.57 to 1.04)
1937
(4 studies)
⊕⊕©©
low5,6
0 per 1000 0 per 1000
(0 to 0)
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Medium risk population4
64 per 1000 49 per 1000
(36 to 67)
High risk population4
190 per 1000 146 per 1000
(108 to 197)
Maternal anaemia Low risk population1 RR 0.64
(0.43 to 0.94)
2401
(3 studies)
⊕⊕⊕⊕
high
178 per 1000 114 per 1000
(77 to 167)
Medium risk population1
456 per 1000 292 per 1000
(196 to 428)
High risk population1
839 per 1000 537 per 1000
(361 to 788)
Maternal infection Low risk population1 RR 0.37
(0.18 to 0.77)
1458
(3 studies)
⊕⊕©©
low7,8
29 per 1000 11 per 1000
(5 to 22)
Medium risk population1
58 per 1000 21 per 1000
(10 to 44)
High risk population1
4
V
ita
m
in
A
su
p
p
le
m
e
n
ta
tio
n
d
u
rin
g
p
re
g
n
a
n
c
y
fo
r
m
a
te
rn
a
l
a
n
d
n
e
w
b
o
rn
o
u
tc
o
m
e
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
1
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
356 per 1000 132 per 1000
(64 to 274)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control event rates sourced from study control groups
2 The authors considered that the pooled effect estimate was not biased by the design of the studies or their analysis of data. Following
correspondence received from the trialists for Kirkwood 2010, the loss to follow-up for this study was 8%: the data from this study are
not at risk of attrition bias.
3 Although the confidence intervals included both a substantial reduction in the risk of death, and a possible small increase in the risk of
death, the low rates of maternal deaths in the control group mean that variation in the absolute effect is small.
4 Of the four studies, medium risk taken from the second lowest as the highest and second highest control event rate were similar (17.48
and 18.97%),
5 The authors have concerns about the accuracy of assessment of gestational age.
6 The confidence interval around the pooled estimate included possible values that indicate a substantial reduction in the risk of maternal
death as well as a small increase in the risk of maternal death with vitamin A.
7 Green 1931 was judged to be at risk of selection and detection bias and strongly influenced the pooled effect estimate.
8 The authors have concerns about the accuracy of the measurement of infection in the studies.
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B A C K G R O U N D
Description of the condition
Vitamin A general
Vitamin A is a fat-soluble vitamin that is derived from two sources:
preformed retinoids and provitamin carotenoids. Retinoids, such
as retinal and retinoic acid, are found in animal sources like liver,
kidney, eggs, and dairy produce. Carotenoids like beta-carotene
are found in plants such as dark or yellow vegetables and carrots.
Carotenoids can be converted to vitamin A in the liver where
vitamin A is stored. Absorption from plant sources is thought to
be low and animal sources (i.e. including dairy products) may be
needed to achieve adequate levels (Borel 2005; Tang 2005).
The digestion and absorption of vitamin A is closely associated
with lipid absorption. Factors such as low dietary fat intake or
intestinal infections may interfere with the absorption of vitamin
A (Mahalanabis 1979; Sivakumar 1972).
Natural retinoids are present in all living organisms, either as pre-
formed vitamin A or as carotenoids, and are required for a vast
number of biological processes including vision, gene transcrip-
tion, immune function, bone metabolism, haematopoiesis, skin
health and antioxidant activity (Combs 2008; McGuire 2007).
Sufficient stores (in the liver) may be able to maintain a person’s
requirement for months (FAO and WHO 2002).
In humans, vitamin A has three active forms (retinal, retinol and
retinoic acid) and a storage form (retinyl ester). The absorption
of vitamin A depends on the amount of lipids ingested in the
diet, with lipids increasing uptake of beta - carotene and vita-
min A (Lidén 2006). Beta-carotene can be cleaved into retinoids
in the liver and the intestines by enzymes known as carotenoid
oxygenases, via two pathways - central or eccentric cleavage.
Central cleavage uses beta-carotene-15,15’-monooxygenase (EC
1.14.99.36), whereby beta-carotene is cleaved at its central 15,15’-
double bond to yield two retinal molecules, which are then con-
verted to two molecules of retinol (vitamin A). Eccentric (or asym-
metric) cleavage splits beta-carotene at double bonds other than
the central one, yielding beta-apocarotenals of different chain
lengths and carotenoic acids, which can then be converted to
one molecule of retinol. Under normal physiological conditions,
central cleavage is the predominant pathway (Lidén 2006; Moffa
1970; Von Lintig 2000).
Circulating vitamin A is transported in plasma in a 1:1 complex
with retinol-binding protein (RBP). RBP is bound to thyroxine
binding pre-albumin (TBPA) and this complex functions as a vi-
tamin A transport system. Binding is specific for vitamin A and
RBP is the only carrier of retinol in plasma.
The retina and other vitamin A dependent tissues have specific
binding sites forRBP and vitaminA.RBP is reduced in proteinuria
whichmay pose a serious threat for transport of retinol to tissues. In
conditions like kwashiorkor (protein malnutrition), levels of RBP
correct with improved protein nutrition even without vitamin A
supplements. RBP is also reduced in zinc deficiency states.
Diseases and conditions that impair the conversion of carotene
to vitamin A or reduce the levels of RBP can contribute to the
development of vitamin A deficiency as RBP is the main transport
protein for Vitamin A.
Vitamin A in pregnancy and the newborn
In pregnancy, some extra vitamin A is required for growth and
tissuemaintenance in the fetus, for providing fetal reserves, and for
maternal metabolism. Pregnant women have a basal requirement
of 370 mcg/d (microgram/day), maximum dose of 3000 mcg/d
and recommended daily allowance (RDA) of 770 mcg/d (FNB
2001; Stipanuk 2006; WHO 1995). In the non-pregnant woman
(or pre-pregnancy) the daily basal requirement is estimated to be
300 mcg/d with a RDA of 700 mcg/d (Stipanuk 2006; WHO
1995). Generally it is considered that liver stores are sufficient to
cover these extra needs in non-vitamin A deficient populations.
There are potentially adverse effects associated with Vitamin A
supplementation during pregnancy. In the first 60 days post-con-
ception, retinol is thought to be teratogenic (Rothman 1995;
WHO 1998). A relationship has been suggested between the in-
cidence of birth defects and high vitamin A intakes during preg-
nancy, with an apparent threshold of near 10,000 international
units (IU) per day (Mills 1997; Rothman 1995). Increased mater-
nal levels of preformed vitamin A (retinoic acid) have been shown
to be associated with miscarriage and with malformations involv-
ing the central nervous and cardiac systems (Miller 1998; WHO
1998). A World Health Organization (WHO) expert group con-
sultation concluded that daily doses of up to 10,000 IU (equiv-
alent to 3000 mcg retinol) or 25,000 IU weekly after day 60 are
probably safe, especially in areas where vitamin A deficiency is
thought to be common (WHO 1998).
The UK National Institute for Health and Clinical Excellence
(NICE) guidelines advise that, owing to potential teratogenic ef-
fects, women in developed (non vitamin A deficiency) countries
should avoid taking vitamin A supplements and liver; in other
words, avoiding the intake of vitamin A above 700 mcg per day
(NCCWCH 2008).
During pregnancy, vitamin A is transferred to the fetus via the
placenta by active mechanisms that maintain the transfer over a
wide range of maternal dietary intake. In contrast, during lacta-
tion, vitamin A concentration in breast milk is more sensitive to
variations in maternal intake (Ross 1994). The estimated require-
ment for vitamin A in newborn infants up to six months of age is
180 mcg/d, with a safe intake level of 350 mcg/d.
Newborn infants normally have a low level of vitamin A in the
liver and they increase these stores in the first few months if the
breast milk has adequate levels. Preterm infants have reduced hep-
atic (liver) stores and lower levels of retinol binding protein (the
vitamin A carrier protein) in the plasma compared to babies born
at term. Insufficient intake and reduced absorption by the imma-
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ture gut may exacerbate deficiencies in preterm infants (Darlow
2007).
Measurement of vitamin A status
In the literature on vitamin A, authors have used a variety of differ-
ent indicators and units of measurement. This can be confusing.
In general, the following conversions can be used:
• serum retinol 1 µmol/l = 28.6 µg/dl or 10 µg/dl = 100 µg/l
= 0.35 µmol/l;
• for supplement doses 1 µg retinol equivalent = 0.00349
µmol retinol = 3.33 IU vitamin A or, expressed differently, 1 IU
vitamin A = 0.3 µg retinol and 0.00105 µmol retinol.
For this review we will endeavour to report whenever known the
supplemented dose of Vitamin A given in or converted to IU.
There are problems associated with the biochemical assessment
of vitamin A deficiency. Serum retinol, because of homeostatic
control exerted by the liver, is not a good general indicator of
vitamin A status.
Serum retinol levels reflect liver vitaminA stores onlywhen they are
severely depleted (less than 0.07 µmol/g liver) or extremely high
(more than 1.05 µmol/g liver). Between these extremes, serum
retinol is homeostatically controlled and thus not always correlated
with vitamin A intake or clinical signs of deficiency. Consequently,
serum retinol is not useful in assessing the vitamin A status of
individuals. Rather, the distribution of serum retinol values in
populations, and the prevalence of individuals with serum retinol
values below a given cut off, can provide important information on
the vitamin A status of a population and can indicate the severity
of vitamin A deficiency as a public health problem (Sommer
1995; WHO 1996). Serum retinol concentrations of 1.05, 0.70
and 0.35 µmol/l have been used in the published literature to
indicate inadequate, moderately inadequate and very inadequate
liver stores respectively (Underwood 1990).
Clinical manifestations of vitamin A deficiency
Symptoms of vitamin A deficiency include a variety of eye symp-
toms, such as night blindness, xerophthalmia (dry eyes, failure to
produce tears), keratomalacia (drying and clouding of the cornea
with ulceration), Bitot spots (keratin debris in the conjunctiva) and
photophobia. Follicular hyperkeratosis (excessive development of
keratin in hair follicles), which is also seen with general malnu-
trition, can be a manifestation of vitamin A deficiency. Ocular
changes can be documented quantitatively using a dark adapta-
tion test (e.g. the papillary threshold test - PTT) or using elec-
troretinography. Often change in night blindness is assessed via
a simple before (the intervention) and after ( the intervention or
treatment) questionnaire. In babies born prematurely, symptoms
of vitamin A deficiency include bronchopulmonary dysplasia (a
form of chronic lung disease).
Night blindness is thought to be one of the first signs of vitamin
A deficiency, followed by a diminished ability to fight infections
especially respiratory and gastroenteric infections (Sommer 1982;
Stephens 1996).
Description of the intervention
Vitamin A supplementation
In non-pregnant populations, vitamin A supplementation to-
gether with iron has led to improved haemoglobin levels in a
number of studies (Bloem 1990; Mejia 1988). Fortification of
food stuffs with vitamin A in Guatemala (sugar) and Indonesia
(monosodium glutamate) was reported to improve ferritin levels
(Mejia 1982) and haemoglobin concentration (Muhilal 1988). In-
tervention studies in Indonesian girls showed that a multivitamin
regimen including vitamin A together with iron supplementation
was more effective than iron alone or a multivitamin without vi-
tamin A for improving ferritin levels (Angeles-Agdeppa 1997).
Trials of vitamin A supplementation to reduce the risk of mother-
to-child transmission of HIV infection in HIV-positive pregnant
women and the effect of vitamin A supplementation in the post-
natal period are reviewed in separate Cochrane reviews (Oliveira
2008; Wiysonge 2008).
An early study suggested that vitamin A supplementation at time
of delivery (oral not intramuscular) may result in an increase of
vitamin A in colostrum (Ajans 1965).
A number of studies have assessed the role of vitamin A sup-
plementation on infectious mortality and morbidity in children
in developing countries. These have been systematically reviewed
(Glasziou 1993). Vitamin A supplementation was associated with
a 30% reduction of death with a larger reduction (66%) in chil-
dren hospitalised with measles. Similar results were found in an-
other review (Fawzi 1993).
How the intervention might work
Vitamin A deficiency
Formany countries there are still no accurate data on vitaminA sta-
tus of pregnant women. However, in areas where night blindness is
common, vitamin A deficiency is often assumed to be widespread.
Vitamin A deficiency is thought to be a significant problem in
many developing countries in Africa, South and South-East Asia
and areas of Latin America and theWestern Pacific (WHO 1995).
Reports of population deficiency are often based on the assessment
of night blindness and other eye symptoms among pre-school chil-
dren in various countries. The most obvious deficiency signs are
dryness of the conjunctiva and the cornea (xerophthalmia), which
can lead to permanent eye damage (McGuire 2007).
It is also known that a diet devoid of vitamin A results in decreased
haemoglobin levels (Hodges 1978). Vitamin A deficiency has been
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found to co-exist with iron deficiency in a number of developing
countries (Karyadi 1996). Several international studies have doc-
umented a positive association between serum retinol and hae-
moglobin concentration in children (Mejia 1977; Wolde-Gabriel
1993) and pregnant women (Suharno 1992). Anaemia in preg-
nancy has been associated with vitamin A deficiency (Van den
Broek 1998; Van den Broek 2000).
Vitamin A is involved in the growth and differentiation of epithe-
lial tissues and also has a role in immunoprotection (Thurnham
1989; Tomkins 1989). Infections most closely associated with vi-
tamin A deficiency are those in which structure or function of
the epithelium may be impaired such as measles, diarrhoea and
respiratory disease. Febrile infections are associated with reduced
serum levels of retinol binding protein and retinol. This is thought
to be an acute phase reaction (Cox 2006; Long 2007). On the
other hand, infection and inflammation can depress serum retinol
values, as can other micronutrient deficiencies (Thurnham 1989;
Tomkins 1989).
Other changes associated with vitamin A deficiency include im-
paired immunity, and squamous metaplasia of the epithelium lin-
ing the upper respiratory passages and urinary bladder leading to
a keratinised epithelium. In relation to dentistry, a deficiency in
vitamin A leads to enamel hypoplasia (Underwood 1994; WHO
1995).
Finally, there is some evidence that dietary carotenoids have pro-
tective function against some human cancers (Rousseau 1992).
Why it is important to do this review
Vitamin A supplementation in pregnancy
Currently, theWHO recommends routine vitamin A supplemen-
tation during pregnancy or at any time during lactation in areas
with endemic vitamin A deficiency (where night blindness occurs)
(WHO 1998). The principal forms used as nutritional supple-
ments are vitamin A palmitate (retinyl palmitate) and vitamin A
acetate (retinyl acetate) but carotenoids (most commonly beta-
carotene) and retinoids (retinol, retinal, retinoic acid) can also be
used as nutritional supplements (DRI 2001).
VitaminA supplementationduringpregnancy and (extended into)
the postnatal period may be expected to affect outcomes such as
maternal and newborn mortality, maternal and newborn anaemia
or infection or other morbidity and there is also a need to docu-
ment if supplementation with vitamin A has been associated with
any harmful effects. A number of new trials have been published
since the first review on vitamin A supplementation for pregnancy
outcomes in 2002 (Van den Broek 2002) and it is therefore im-
portant to review all current evidence regarding vitamin A sup-
plementation to inform and review the existing recommendations
for practice.
O B J E C T I V E S
To review the effectiveness of the supplementation of vitamin A
or one of its derivatives during pregnancy, alone or in combina-
tion with other vitamins and minerals, on maternal and newborn
clinical and laboratory outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised or quasi-randomised trials, including cluster-ran-
domised trials, evaluating the effect of vitamin A supplementation
in pregnant women.
We excluded trials where vitamin A is given only in the postnatal
period but included trials where vitamin A was commenced pre-
pregnancy or during pregnancy and continued into the postnatal
period.
The outcome ’HIV transmission’ was not considered in this review
as it is covered in another review (Wiysonge 2008) but we included
data from randomised controlled trials (RCTs) aimed at prevent-
ing vertical transmission if they meet our criteria for inclusion and
report obstetric and infant outcomes relevant to our review. In ad-
dition, this current review is different fromHaider 2008 which re-
views the effects of multi-micronutrient supplements which could
include vitamin A but does not assess the effect of vitamin A alone.
Types of participants
Pregnant women receiving vitamin A supplementation either in
areas with endemic vitamin A deficiency (inadequate intake) or in
areas with adequate intake as defined by theWHO global database
on vitamin A deficiency.
Types of interventions
Vitamin A (or one of its derivatives) supplementation, alone or
in combination with other supplements compared with a control
group. The control group could be placebo, no treatment or an-
other intervention (for example, iron).
Researchers report vitamin A measurements in different units. Ac-
cordingly, we used the following tables for conversions: Table 1;
Table 2.
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Table 1. Retinol supplementation to vitamin A conversion table
Retinol supplementation in mcg Vitamin A in IU
1 3.33
2 6.66
3 9.99
Table 2. Serum retinol conversion table
Serum retinol mcg/dl Serum retinol mc mol/L
10 0.35
20 0.7
30 1.05
Comparisons included: vitamin A (or derivative)
1. alone versus placebo or no treatment;
2. alone versus micronutrient supplements (may include iron
or/and folic acid) without vitamin A;
3. in combination with other micronutrients versus
micronutrient supplements without vitamin A.
Types of outcome measures
The outcomes of this review are maternal and perinatal clinical
outcomes.
This review focuses on effects on maternal and newborn mortality
and morbidity such as anaemia and infection (but not on HIV
which is reviewed elsewhere).
We sought information on the following outcomes for this review.
Primary outcomes
1. Maternal mortality (defined as the death of a woman while
pregnant or within 42 days of termination of pregnancy,
irrespective of the duration and site of the pregnancy, from any
cause related to or aggravated by the pregnancy or its
management but not from accidental or incidental causes
(ICD-10 2007)).
2. Perinatal mortality (defined as number of stillbirths and
deaths in the first week of life per 1000 live births (HAP 2008;
PNM 2005)).
Secondary outcomes
1. Neonatal mortality (defined as the number of deaths during
the first 28 completed days of life per 1000 live births in a given
year or period (PNM 2005)).
2. Stillbirths (as defined by the trial author).
3. Maternal anaemia ((Hb) less than 11.0 g/dl).
4. Maternal clinical infection (as defined by the investigator).
5. Maternal night blindness (reported or with demonstrable
ocular lesion or abnormal adaptation test).
6. Preterm birth (less than 37+0 weeks gestational age).
7. Neonatal anaemia (as defined by investigator).
8. Neonatal clinical infection (as defined by investigator).
9. Congenital malformations (any reported).
10. Low birthweight (less than 2.5 kg).
Where outcomes were not given according to the definitions spec-
ified above, we have noted this in the summary tables and included
outcomes in the analyses wherever possible.
Search methods for identification of studies
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (15
July 2010).
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The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies we identified as a result of the search strategy
and a third author reviewed these. We resolved any disagreement
through discussion.
Data extraction and management
We designed a form to extract data. For eligible studies, two re-
view authors independently extracted the data using the agreed
form, and a third author checked these. We resolved discrepancies
through discussion. We entered data into Review Manager soft-
ware (RevMan 2008) and checked them for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2009). We resolved
any disagreement by discussion or by involving a third assessor.
(1) Sequence generation (checking for possible selection
bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• adequate (any truly random process, e.g. random number
table; computer random number generator);
• inadequate (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number); or
• unclear.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence and determine whether intervention allo-
cation could have been foreseen in advance of, or during recruit-
ment, or changed after assignment.
We assessed the methods as:
• adequate (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear.
(3) Blinding (checking for possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received.We considered that studies are
at low risk of bias if they were blinded, or if we judged that the
lack of blinding could not have affected the results. We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• adequate, inadequate or unclear for participants;
• adequate, inadequate or unclear for personnel;
• adequate, inadequate or unclear for outcome assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or can be supplied by
the trial authors, we will re-include missing data in the analyses
which we undertake. We assessed methods as:
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• adequate (where there was no or less than 20% missing data
and where reasons for missing data are balanced across groups);
• inadequate (where more than 20% participants’ data are
missing or where data are not balanced across groups);
• unclear.
(5) Selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• adequate (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• inadequate (where not all the study’s pre-specified outcomes
have been reported; one or more reported primary outcomes were
not pre-specified; outcomes of interest are reported incompletely
and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported);
• unclear.
(6) Other sources of bias
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• yes;
• no;
• unclear.
(7) Overall risk of bias
Wemade explicit judgments about whether studies are at high risk
of bias, according to the criteria given in theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2009). With reference
to (1) to (6) above, we assessed the likely magnitude and direction
of the bias and whether we considered it is likely to impact on
the findings. We explored the impact of the level of bias through
undertaking sensitivity analyses - see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used themean difference if outcomeswere
measured in the sameway between trials.We used the standardised
mean difference to combine trials that measure the same outcome,
but used different methods.
Unit of analysis issues
Cluster-randomised trials
We included cluster-randomised trials in the analyses along with
individually randomised trials, using the generic inverse method
to combine studies using different designs. The standard errors of
the two cluster randomised trials were inflated using an estimate
of the intracluster correlation co-efficient (ICC) derived from data
in the trial reports, as described in the Cochrane Handbook for
Systematic Reviews of Interventions, section 16.3.6 (Higgins 2009)
using an estimate of the ICC derived from the trial (if possible),
from a similar trial or from a study of a similar population. If we
used ICCs from other sources, we reported this and conducted
sensitivity analyses to investigate the effect of variation in the ICC.
If we identified both cluster-randomised trials and individually-
randomised trials, we synthesised the relevant information. We
considered it reasonable to combine the results from both if there
was little heterogeneity between the study designs and the inter-
action between the effect of intervention and the choice of ran-
domisation unit was considered to be unlikely.
We also acknowledged heterogeneity in the randomisation unit
and performed a subgroup analysis to investigate the effects of the
randomisation unit.
Dealing with missing data
For included studies, we noted levels of attrition. We explored the
impact of including studies with high levels of missing data in the
overall assessment of treatment effect by using sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes are known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if T² was greater than zero and either I² was greater than
30% or there was a low P value (less than 0.10) in the Chi² test
for heterogeneity.
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Assessment of reporting biases
If there were 10 or more studies in the meta-analysis, we investi-
gated reporting biases (such as publication bias) using funnel plots.
We assessed funnel plot asymmetry visually, and use formal tests
for funnel plot asymmetry. For continuous outcomes we used the
test proposed by Egger 1997, and for dichotomous outcomes we
used the test proposed by Harbord 2006. If we detected asymme-
try in any of these tests or by a visual assessment, we performed
exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2008).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were es-
timating the same underlying treatment effect: that is, where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar. If there was clinical
heterogeneity sufficient to expect that the underlying treatment ef-
fects differed between trials, or if substantial statistical heterogene-
ity was detected, we used random-effects meta-analysis to produce
an overall summary if an average treatment effect across trials was
considered clinically meaningful. We treated the random-effects
summary as the average range of possible treatment effects and we
discussed the clinical implications of treatment effects differing
between trials. If the average treatment effect was not clinically
meaningful we did not combine trials.
If we used random-effects analyses, we presented the results as the
average treatment effect with its 95% confidence interval, and the
estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated it using
subgroup analyses and Sensitivity analysis.We considered whether
an overall summary was meaningful, and if it was, used random-
effects analysis to produce it.
We plan to carry out the following subgroup analyses.
1. Countries with high versus low infant mortality rates (high
infant mortality rate greater than or equal to 30/1000 live births
(IMCI- TAG 2008)).
2. Countries with high versus low maternal mortality rates
(high maternal mortality rate greater than 100 per 100,000 live
births (WHR 2005)).
3. High versus low prevalence of vitamin A deficiency (as
defined by WHO for the country or by the investigator).
4. Countries with a low versus high prevalence of HIV in the
general population (high-prevalence countries defined as
countries with national prevalence that exceeded 3% of the
general population (AIDS Report 2008)).
5. Dose daily 10,000 IU versus other doses.
6. Regimen: daily versus weekly.
7. Duration of intervention: by number of weeks
8. Trimester of pregnancy in which supplementation was
started (prepregnancy supplementation versus first trimester
versus second trimester versus third trimester).
We used only primary outcomes in subgroup analysis.
For fixed-effect inverse variance meta-analyses, we assessed dif-
ferences between subgroups by interaction tests. For random-ef-
fects and fixed-effect meta-analyses using methods other than in-
verse variance, we assessed differences between subgroups by in-
spection of the subgroups’ confidence intervals; non-overlapping
confidence intervals indicate a statistically significant difference in
treatment effect between the subgroups.
Sensitivity analysis
We carried out sensitivity analyses to explore the effect of trial
quality for important outcomes in the review. Where there was
risk of bias associated with a particular aspect of study quality (e.g.
inadequate allocation concealment), we explored this by sensitiv-
ity analyses. We explored only primary outcomes by sensitivity
analyses.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
Initially we examined 88 reports of 31 trials, published between
1931 and 2010, for inclusion in this review. We included 16 trials
and excluded 14. One trial awaits classification (Hakimi 1999).
Included studies
For detailed characteristics of the included studies, see
Characteristics of included studies.
Of the 16 included trials, two were cluster-randomised (Kirkwood
2010; West 1999) while the rest were based on randomisation of
individual women. Only two trials were quasi-randomised (Green
1931; Suprapto 2002). One trial was conducted in the UK (Green
1931) and one in the USA (Ajans 1965).
Seven trials were conducted inAfrica: three inMalawi (Kumwenda
2002; Semba 2001; van den Broek 2006), one in South Africa
(Coutsoudis 1999), two in Ghana (Cox 2005; Kirkwood 2010)
and one in Tanzania (Fawzi 1998). Five of the included trials were
conducted in Indonesia (Dijkhuizen 2004; Muslimatun 2001;
Suharno 1993; Suprapto 2002; Tanumihardjo 2002). One trial
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was conducted in India (Radhika 2003) and one in Nepal (West
1999).
All trials were conducted in populations considered to be moder-
ately vitamin A deficient before the relevant trial was commenced
except three trials: West 1999 was conducted in Nepal in which
the population was considered to be severely deficient in vitamin
A (FAO and WHO 2002; FNB 2001; WHO 1996) two trials in
USA and UK were conducted in populations which were not a
considered Vitamin A deficient (Ajans 1965 and Green 1931).
Two trials were specifically designed withmaternal mortality as the
primary outcome. Women of reproductive age were given weekly
Vitamin A supplements:
In the Nepal trial byWest 1999, more than 36,800 deliveries were
analysed as part of a cluster-randomised field trial conducted in
South-East Nepal among a total of 30 village development com-
munities (VDC),which are small sub-districts, each ofwhich com-
prises nine wards. A total of 270 wards were randomised to three
groups of 90 each, including 44,646 women of reproductive age
receiving a weekly single oral supplement of vitamin A (23 310
IU vitamin A or 7000 mcg retinol equivalents) or beta carotene
(42 mcg, or 7000 mcg retinol equivalent) or placebo. Local field
workers visited the women weekly at home and administered the
supplements. Pregnant women were eligible to be included in the
analysis if they had received supplements for at least five months
before conception. The primary outcome of the trial was preg-
nancy related and direct mortality occurring up to 12 weeks post-
partum and included injury related deaths. Baseline characteris-
tics such as age, arm circumference, diet or socioeconomic sta-
tus were similar between the three groups. Compliance was as-
sessed biochemically and through interviews. Serum retinol and
beta-carotene concentrations were measured at mid-pregnancy in
a sub-sample of women to assess compliance. Levels for vitamin
A and beta-carotene were found to be raised in the supplemented
(not placebo) groups and taken to imply good compliance with
intake of supplements. It was noted that pregnant women were
more likely to have received their supplements than women who
did not become pregnant during the period of the trial. More than
75% of pregnant women received at least half their eligible doses
of supplement but only half received 80% or more of the intended
supplement.
The trial fromGhana, Kirkwood 2010, is the largest trial with the
inclusion of more than 207,000 pregnant women. This was a clus-
ter-randomised trial. All women aged 15 to 45 years living in seven
predominantly rural districts in Brong Ahafo Region in Ghana
who were capable of giving informed consent and who planned
to live in the trial area for at least three months were eligible for
enrolment. Implementation was phased by district; field workers
visited all compounds over a four- to eight-week period. Women
were randomly assigned, according to their cluster of residence,
to receive a vitamin capsule or placebo capsule orally once every
week. The vitamin A capsule consisted of 25 000 IU (7500 µg)
retinol equivalents in soybean oil in a dark red opaque soft gel.
The placebo capsule consisted of soybean oil only. Women were
visited at home every four weeks, and given four capsules to be
taken over the next four weeks; capsules were kept in vials, with
cotton wool to absorb humidity in the rainy season. There was no
direct observation of capsule taking during home visits. Instead,
adherence was supported by an extensive information, education,
and communication (IEC) programme, based on formative re-
search undertaken before the trial began, with women encouraged
to take their capsules on the same day, Sunday, to foster social
support and reduce forgetfulness. Randomisation was by cluster
to keep the possibility of women receiving the wrong capsules to
a minimum. The primary outcomes of the trial were pregnancy-
related mortality and all-cause female mortality. Secondary out-
comes were severe maternal morbidity and perinatal and infant
mortality.
A total of eight trials specifically assessed the effect of Vitamin A
on haemoglobin levels. Vitamin A was given during the antenatal
period in combination with other micronutrients, generally iron
and folic acid.
There are five studies from Indonesiawhich assess effect ofVitamin
A on haemoglobin.
Suharno 1993 included 305 women from 20 rural villages inWest
Java, 16 to 24 weeks pregnant, with haemoglobin concentrations
between 8.0 and 10.9 g/dl. Women were assigned to one of four
groups to receive daily supplements: one group received vitamin A
(2.4 mg retinol as retinyl palmitate which equates to about 8000
IU vitamin A) and placebo iron tablets; the second group received
iron (60 mg elemental iron as ferrous sulphate) and placebo vi-
tamin A; the third group received both the vitamin A and iron
supplements (as described in groups one and two); and the fourth
group received placebos only. Blood samples for haematologic pa-
rameters were taken before supplementation (which lasted two
weeks) and two to seven days after the last supplements were given.
The supplements were administered under the direct daily super-
vision of field workers.
In Tanumihardjo 2002, pregnant women in the second or early
third trimester were recruited from the suburban areas of Bogor
in West Java, Indonesia. Ages ranged from 18 to 37 years and
parity from 0 to 4 children.Women were randomly assigned to the
following four supplementation groups: placebo, 8.4 mol (8000
IU) vitaminA as retinyl palmitatewith an iron placebo, 1.07mmol
(60 mg) ferrous sulfate with a vitamin A placebo and vitamin
A plus iron. The daily supplementation was monitored using a
control card and check list by the volunteers who were responsible
for administration of the doses.
Suprapto 2002 was a quasi-randomised trial. It took place in the
rural area of Banyudono subdistrict, Boyolali regency, Central
Java province, Indonesia. All pregnant women who visited the
Banyudono health centres’ antenatal clinics from July to Novem-
ber 2000 were asked to participate in the study. All pregnant
women were numbered and listed. They were then allocated alter-
nately into groups according to their numbers. Group IF (n = 29)
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received iron-folate tablets + 5 mg glucose (placebo); group IFR
(n = 22) received iron-folate tablets + 5 mg riboflavin; group IFA
(n = 29) received iron-folate tablets + 2.75 mg retinyl palmitate
(equal to 5000 IU vitamin A); and group IFRA (n = 23) received
iron-folate tablets + 5 mg riboflavin + 2.75 mg retinyl palmitate.
These were administered seven days a week for 60 days.
Muslimatun 2001 was carried out in the rural subdistrict of
Leuwiliang, West Java, Indonesia. Pregnant women were sup-
plemented once weekly from enrolment until delivery with two
tablets each containing 60 mg iron as ferrous sulfate and 250 mg
folic acid or with two tablets each containing 2400 retinol equiv-
alents (RE) vitamin A in addition to the same amount of ferrous
sulfate and folic acid.
In Dijkhuizen 2004 all women were recruited before 20 weeks’
gestational age from13 adjacent villages in a rural area in Bogor
District, West Java, Indonesia. Each woman was supplemented
daily during pregnancy until delivery. All women received iron and
folic acid (30 mg iron as ferrous fumarate/d and 0.4 mg pteroyl-
glutamic acid/d). In addition, one group of women received -
carotene (4.5 mg as water-soluble granulate/d; -carotene group),
one group received zinc (30 mg zinc as sulfate/d; zinc group), one
group received -carotene plus zinc (4.5 mg -carotene and 30 mg
zinc/d; -carotene zinc group), and one group received only iron
and folic acid (control group).
There are two trials fromMalawi where the primary outcome was
effect of Vitamin A on haemoglobin.
The Semba 2001 trial was conducted in women attending a teach-
ing hospital antenatal clinic. Pregnant women were given daily
supplements of either vitamin A (3000 mcg retinol equivalent
which equals 10,000 IU vitamin A) or placebo. All women re-
ceived daily iron (30 mg) and folate (400 mcg). In addition, all
women received two doses of Fansidar during pregnancy as pre-
sumptive treatment for malaria. Outcomes were measured at 38
weeks and included haemoglobin concentration and erythropoi-
etin. Iron status was measured using serum ferritin and markers of
inflammation included C-reactive protein and alpha-acid glyco-
protein. VitaminA status wasmeasured using serum retinol. Com-
pliance with supplements was assessed via monthly tablet counts.
The van den Broek 2006 trial included a representative group
of rural women attending antenatal clinic in southern Malawi.
Women received daily supplements of either vitamin 10,000 IU or
vitamin A 5000 IU or a placebo. In addition, all women received
daily iron supplements (60 mg elemental iron as ferrous sulphate
with 0.25 mg folic acid). All women also received presumptive
malaria treatment at around 20 and 34 weeks’ gestation consist-
ing of three tablets of Fansidar (500 mg sulphadoxine with 25
mgpyrimethamine). Inclusion criteria includedhaemoglobin level
less than or equal to 11.0 g/dl and more than 5.0 g/dl after deter-
mination of haemoglobin using the HemoCue screening method.
Subsequent haemoglobinmeasurements weremade using an auto-
mated (Coulter) counter. Thirty-two per cent of women recruited
were HIV-positive. Mean duration of supplementation was 14
weeks. Gestational age at recruitment was not less than 12 weeks
and not more than 24 weeks as assessed by ultrasonography. Blood
samples were taken before supplementation was commenced and
for up to two times during the antenatal period and two times
postnatally. Vitamin A status was determined using serum retinol
as well as the modified relative dose response test (MRDR). Iron
status was measured using serum ferritin and serum transferrin re-
ceptor levels.Measures of infection status included C-reactive pro-
tein (CRP), malaria andHIV status. Compliance was measured by
two-weekly tablet counts and serum retinol measurements. The
three main outcome measures were haemoglobin level, prevalence
of anaemia ((Hb) < 11.0 g/dl) and severe anaemia ((Hb) < 8.0 g/
dl) after supplementation. Secondary outcomes included vitamin
A status, iron status and infection status.
One study from India assessed effect of antenatal supplementation
on haemoglobin levels.
Radhika 2003 is a randomised clinical trial of red palm oil sup-
plementation and was conducted in pregnant women attending
the outpatient department of Niloufer Hospital, Hyderabad, In-
dia, between January 2001 and March 2002. The women in the
experimental group received red palm oil providing 2173 to 2307
µg of β-carotene per day with a dosage schedule of one sachet per
day (8 ml). The women in the control group received one sachet
of groundnut oil (8 ml). A detailed clinical anthropometric and
obstetric examination was conducted in all the women at baseline
and every two weeks up to 36 weeks and thereafter every week
until delivery. All the women received iron folate tablets (60 mg
of iron and 500 µg of folic acid) for 100 days and routine prenatal
care.
Three trialswere conducted inHIV-positive pregnantwomenwith
the main intent of looking at the effect of Vitamin A supplemen-
tation on mother to child transmission of HIV. These trials also
report on other outcomes relevant to this review and are included.
In the trial by van den Broek 2006 in rural Malawi, 32% of all
recruited women were HIV-positive but this trial was designed to
assess effect of Vitamin A on haemoglobin levels and HIV trans-
mission was not measured.
In Kumwenda 2002 the study population consisted of HIV-posi-
tive pregnant women of 18 to 28 weeks’ gestation who were seen at
the antenatal clinic of theQueenElizabethCentralHospital (Blan-
tyre, Malawi) fromNovember 1995 through December 1996. All
women received orally administered daily doses of iron (30 mg of
elemental iron) and folate (400 mg) from the time of study enrol-
ment until delivery. One-half of the women were randomised to
receive daily doses of orally administered vitamin A (3 mg retinol
equivalent (10,000 IU); the vitamin A group) from the time of
study enrolment until delivery.
One trial was conducted in the republic of South Africa:
Coutsoudis 1999 is a double-blind randomised trial conducted in
King Edward VIII Hospital and McCords Hospital, in Durban,
South Africa. HIV-positive women of 28 to 32 weeks’ gestation
were randomised to receive either placebo or a daily dose of 5000
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IU retinyl palmitate and 30 mg beta-carotene during the third
trimester of pregnancy and 200,000 IU retinyl palmitate at deliv-
ery.
One study from Tanzania: Fawzi 1998 recruited pregnant women
between 12 and 27 weeks’ gestation who were HIV infected and
resident in Dar es Salaam. Women were assigned in a two-by-two
factorial design. One thousand and seventy-five women received
a daily oral dose of: vitamin A (30 mg beta-carotene plus 5000 IU
preformed vitamin A, n = 269); multivitamins excluding vitamin
A (20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 µg B12,
500 mg C, 30 mg E, and 0·8 mg folic acid, n = 269); multivita-
mins including vitamin A (n = 270), all formulated in two tablets;
or two tablets of placebo (n = 267). Eighty-five per cent of women
took the single large dose of the supplement or placebo at delivery;
the other 15% were not given this dose because they delivered at
home or at another clinic. Compliance was assessed as the per-
centage of prescribed tablets absent from the returned bottles. To
further assess compliance, plasma vitamin A concentrations were
measured at baseline and at delivery in 100 women.
For three trials themain outcome measure was maternal infection.
Ajans 1965 conducted a study in the USA in which 44 parturient
women in good health from the lower and middle socioeconomic
groups were allotted at random to one of three groups after ad-
mission to the delivery suite of the American University Hospital.
Group one included 18 women who were not given any form of
vitamin A therapy prepartum; they formed the control group of
the study. Group two comprised 15 women who were all given a
single intramuscular injection of 600,000 lU of vitamin A palmi-
tate in oil at parturition. Group three was made up of 11 women
who were given 600,000 lU of water-dispersible vitamin A palmi-
tate orally shortly before delivery. Blood samples were collected
from all women before delivery and, in the case of groups two
and three, before dosing with vitamin A. Four samples of 2 ml
to 3 ml of colostrum were also collected from each woman: one
antepartum sample and three postpartum samples, one on each
consecutive day of hospitalisation. Following discharge, women
in group three were followed up further by public health nurses at
their homeswhere bi-weekly samples ofmilkwere collected during
the first week after discharge and then weekly samples for a total
period ranging between 38 and 59 days postpartum. Women in
groups one and two were studied in the summer (June to August
1963) and those of group three in the following winter (October
1963 to March 1964). Group three was excluded from analysis in
this review because they were conducted in a different time and
conditions than the other two groups.
Green 1931 is a quasi-randomised trial conducted in the Jessop
Hospital and the Nether Edge municipal hospital in the UK. Six
hundred women were recruited. All women not delivered in hos-
pital were rejected from the series, so that a total of 275 women
treated with the vitamin preparation and 275 untreated to serve as
controls remained for analysis. Vitamin preparation was given as
1 oz of the vitamin preparation radiostoleum, an amount equiva-
lent in vitamins A and D roughly to 30 oz of a good cod-liver oil,
should have been taken commencing one month previous to the
calculated day of labour. The first 76 cases prior to June 1929 were
given the preparation for only 14 days before delivery (daily). It
was, however, continued for the first seven days of the puerperium.
It was then decided that a more logical procedure would probably
be to begin the administration earlier and thus build up a larger
reserve at the time of labour.
Cox 2005 recruited primigravid pregnant women from antenatal
clinics at Nkoranza District Hospital and three rural health clinics
in Brong Ahafo region, Central Ghana. Women were randomised
to either capsules which were given weekly and contained 10,000
IU of vitamin A as retinyl palmitate in groundnut oil, plus toco-
pherol as a preservative from enrolment until six weeks’ postpar-
tum, or groundnut oil and tocopherol only in the placebo capsules
from enrolment until six weeks’ postpartum.
Excluded studies
For detailed characteristics of the excluded trials, seeCharacteristics
of excluded studies.
Of the 14 excluded studies, we excluded two because they used
lycopene as the intervention (Banerjee 2009; Sharma 2003). Ly-
copene lacks beta-ion ring (that is present in the β-carotene),
so lycopene cannot form vitamin A and its biological effects are
due to mechanisms other than forming vitamin A. We excluded
three studies because they were not randomised trials (Chawla
1995; Howells 1986; Laitinen 2009). We excluded four studies
because both arms of the trial contained the same product and
so lacked any comparison (Christian 2003; Haskell 2005; Lietz
2001; Roberfroid 2010). We excluded three studies because the
intervention only started after delivery (Darboe 2007; Humphrey
2006; Roy 1997). We excluded one study because the only out-
come was HIV transmission and although secondary outcomes
are relevant to this review no data are available (Chikobvu 2001).
Finally, we excluded one study because participants were not preg-
nant women (Van Vliet 2001).
Risk of bias in included studies
See Figure 1 and Figure 2.
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
16Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Only four studies did not report at all on the allocation con-
cealment and generation (Ajans 1965; Coutsoudis 1999; Radhika
2003; Tanumihardjo 2002). Two of the included studies were
not clear on the allocation concealment and generation (Cox
2005;Muslimatun 2001). Three studies reported inadequate allo-
cation concealment and generation (Green 1931; Suharno 1993;
Suprapto 2002). The remaining seven trials reported adequate
allocation concealment and generation (Dijkhuizen 2004; Fawzi
1998; Kirkwood 2010; Kumwenda 2002; Semba 2001; van den
Broek 2006; West 1999).
Blinding
All included studies reported on blinding. Only two studies re-
ported no blinding while all other included trials reported double
blinding (Ajans 1965; Green 1931).
Incomplete outcome data
Four studies did not address the incomplete outcome data is-
sue (Dijkhuizen 2004; Muslimatun 2001; Radhika 2003; Semba
2001). The rest of the included trials adequately addressed the
issue of incomplete outcome data. Authors of the Kirkwood 2010
trial provided supplementary data to confirm that although 43%
of womenmigrated out of the trial area and 1%withdrew consent,
the loss to follow up for pregnancy-related mortality was calcu-
lated to be 8%.
Selective reporting
The protocols of the included studies were not generally available
and accordingly we can not comment on selective reporting bias
except for Kirkwood 2010 which was free from any selective re-
porting bias.
Other potential sources of bias
Three studies were unclear, either because only an abstract was
available (Chikobvu 2001), presence of differences in educational
level and gestational age at enrolment (Cox 2005) or the study
report is not detailed enough (Tanumihardjo 2002). Two trials
had a potential source of bias. Suprapto 2002 had reported that
women in group IFRA were shorter and lighter than those in other
groups. The rest of the included trials were free from any potential
source of bias.
Effects of interventions
See: Summary of findings for the main comparison Vitamin
A for maternal and newborn mortality and morbidity; Summary
of findings 2 Combination vitamin A and micronutrients for
maternal and newborn mortality and morbidity
Vitamin A alone versus placebo or no treatment
Vitamin A supplementation does not significantly affect the risk of
maternal mortality (risk ratio (RR) 0.78, 95% confidence interval
(CI) 0.55 to 1.10, three studies; Tau² 0.04, I² 37%; Analysis
1.1), perinatal mortality (RR 1.01, 95% CI 0.95 to 1.07; 1 study,
Analysis 1.2), neonatal mortality (RR 0.97, 95% CI 0.90 to 1.05;
three studies , I² 23% Analysis 1.3) or stillbirth (RR 1.06, 95%
CI 0.98 to 1.14, 1 study; Analysis 1.4).
Vitamin A supplementation does not significantly affect the risk
of neonatal anaemia (RR 0.99, 95% CI 0.92 to 1.08; 1 study,
Analysis 1.9), preterm birth (RR 0.77, 95% CI 0.57 to 1.04, four
studies, I² 0% Analysis 1.8) or the risk of having a low birthweight
baby (RR 0.98, 95% CI 0.62 to 1.54; three studies, Tau² 0.06, I²
23%, Analysis 1.12).
Vitamin A supplementation significantly reduces the risk of ma-
ternal anaemia (RR 0.64, 95%CI 0.43 to 0.94; three studies, Tau²
0.08, I² 68%, Analysis 1.5), maternal clinical infection (RR 0.37,
95% CI 0.18 to 0.77; three studies, Tau² 0.19, I² 39%, Analysis
1.6 ), and maternal night blindness (RR 0.70, 95% CI 0.60 to
0.82; 1 study, Analysis 1.7).
No trials investigated vitamin A alone versus micronutrient sup-
plement without vitamin A.
Vitamin A with other micronutrients versus
micronutrient supplements without vitamin A
Vitamin A supplementation (with other micronutrients) does not
have a significant effect on the risk of stillbirth (RR 1.41, 95% CI
0.57 to 3.47; two studies, Analysis 3.4), maternal anaemia (RR
0.86, 95% CI 0.68 to 1.09; three studies, Analysis 3.5 ) preterm
birth (RR 0.39, 95% CI 0.08 to 1.93; one study, Analysis 3.8),
neonatal mortality (RR 0.65, 95% CI 0.32 to 1.31; one study,
Analysis 3.3 ), or neonatal anaemia (RR 0.75, 95% CI 0.38 to
1.51; two studies, Tau² 0.24, I² 97%, Analysis 3.9). There were
fewer low birthweight babies in the supplemented groups (RR
0.67, CI 0.47 to 0.96; one study, Analysis 3.12).
Subgroup analysis
Only the specified primary outcomes maternal and perinatal mor-
tality were included in the subgroup analysis. Subgroup analysis
was by country statistics for vitamin A deficiency (high or low),
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maternal mortality (high or low), infant morality (high or low)
and HIV status (high or low).
All trials investigating the effects on maternal and perinatal mor-
tality were cluster-randomised trials.
For maternal mortality
In countries with high maternal mortality or high prevalence of vi-
tamin A deficiency, the RR for maternal mortality was 0.83, (95%
CI 0.68 to 1.02) in the overall analysis. There was no significant
reduction in the odds of maternal mortality in countries with low
maternal mortality or low prevalence of vitamin A deficiency (RR
0.33, 95% CI 0.01 to 8.19).
For countries described as having low infant mortality rates, ma-
ternal mortality decreased by two thirds (RR 0.33, 95% CI 0.01
to 9.44) but maternal mortality was not significantly reduced for
countries with high infant mortality rates (RR 0.77, 95% CI 0.51
to 1.17).
In countries with low HIV prevalence the RR for maternal mor-
tality was 0.83 (95% CI 0.68 to 1.01). The trials in countries with
high HIV prevalence did not set out to assess the effect of vitamin
A on maternal mortality.
For perinatal mortality
Perinatal mortality in countries with high infant mortality rates
remained unchanged (RR 1.01, 95% CI 0.95 to 1.07). Perinatal
mortality was not assessed in countries with low infant mortality
rates.
Perinatal mortality in countries with high maternal mortality rates
or high prevalence of vitamin A deficiency remained unchanged
(RR 0.95, 95% CI 0.87 to 1.03). No trials reported on perina-
tal mortality from countries with low maternal mortality rates or
countries with low prevalence of vitamin A deficiency.
In countries with low HIV prevalence, RR for perinatal mortality
was 1.01 (95% CI 0.95 to 1.07). For countries with high HIV
prevalence, no trials investigated the effect of vitamin A supple-
mentation to the mother on perinatal mortality.
Dose of vitamin A
In relation to the dose, no trials investigated the effect of daily
10,000 IU vitamin A supplementation on maternal mortality, but
for other doses the RR for vitaminA supplementation formaternal
mortality was 0.83 (CI 0.68 to 1.02) and for perinatal mortality
1.01 (95% CI 0.95 to 1.07).
For weekly vitamin A supplementation the RR for maternal mor-
tality was 0.83 (95% CI 0.68 to 1.02) and for perinatal mortality
1.01 (95% CI 0.95 to 1.07).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Combination vitamin A and micronutrients for maternal and newborn mortality and morbidity
Patient or population: Pregnant women
Settings: Areas with endemic vitamin A deficiency (inadequate intake)/areas with adequate intake as defined by the WHO global database on vitamin A deficiency
Intervention: Combination vitamin A and micronutrients
Comparison: Other micronutrients
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Other micronutrients Combination vitamin A
and micronutrients
Maternal mortality See comment See comment Not estimable 0
(0)
See comment
Perinatal mortality See comment See comment Not estimable 0
(0)
See comment
Preterm birth 75 per 1000 29 per 1000
(6 to 145)
RR 0.39
(0.08 to 1.93)
136
(1 study)
⊕©©©
very low1,2,3
Maternal anaemia Low risk population RR 0.86
(0.68 to 1.09)
706
(3 studies)
⊕⊕©©
low4,5
136 per 1000 117 per 1000
(92 to 148)
Medium risk population
346 per 1000 298 per 1000
(235 to 377)
High risk population
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667 per 1000 574 per 1000
(454 to 727)
Maternal infection See comment See comment Not estimable 0
(0)
See comment
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 22.2% women were not included in the analyses. The study was at a high risk of attrition bias.
2 The confidence intervals covered a range of values that included a substantial reduction and increase in the risk of preterm birth with
vitamin A.
3 The study protocols were not available, precluding full assessments of the outcomes that were measured but not reported. Publication
bias could not be excluded on this basis.
4 Most of the weight was assigned to studies where there was a high risk of attrition bias.
5 The confidence intervals covered a range of values that included a substantial reduction in the risk of maternal anaemia and a potential
increase in the risk of maternal anaemia with vitamin A.
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D I S C U S S I O N
Summary of main results
This review investigates the effectiveness of vitamin A supplemen-
tation during pregnancy, alone or in combination with other mi-
cronutrients, on maternal and newborn clinical outcomes. Sixteen
trials are included in this review out of a total of 31.
In countries where night blindness is reported, maternal night
blindness is significantly improved with vitamin A supplementa-
tion (RR 0.70, 95% CI 0.60 to 0.82).
We conducted a meta-analysis for the first time in this review;
this had not been possible in the previous review. Although there
are limitations to this, overall the analysis shows that there is no
evidence that Vitamin A supplementation to women of reproduc-
tive age or during pregnancy decreases maternal mortality (RR
0.78, 95% CI 0.55,1.10). In vitamin A deficient populations and
HIV-positive women, vitamin A supplementation reduces mater-
nal anaemia (RR 0.64, 95% CI 0.43 , 0.94) and there is evidence
that vitamin A supplements may reduce maternal clinical infec-
tion (RR 0.37, 95% CI 0.18 to 0.77).
Of the included trials, 13 were designed to measure the effect of
vitamin A supplementation during pregnancy on maternal mor-
tality or maternal anaemia or maternal infection. Other maternal
and neonatal clinical outcomes were also determined in the studies
but not as primary outcomes. Three trials were designed to assess
effect of Vitamin A on mother to child transmission of HIV - we
have included these because the secondary outcomes are relevant
to this review.
The trials are from a variety of countries, including both devel-
oping and high-resource countries, with large differences between
the countries with regard to baseline maternal and perinatal mor-
tality as well as baseline vitaminA status and prevalence of anaemia
of the populations studied. In some studies vitamin A status of
the trial population was assessed specifically at baseline (by serum
retinol levels or using the more accurate Modified Relative Dose
Response (MRDR) test), whereas in other studies this was not
done.
It was difficult to compare the results of supplementation with
Vitamin A (or derivatives) on maternal and newborn health out-
comes, especially where these outcomes were differently defined in
the different studies. For example, maternal clinical infection was
variously defined as temperature above 37 or 38 degrees Celsius at
different times during pregnancy and the postnatal period (e.g. 12
weeks antenatal or one week or three months postnatal); or infec-
tious morbidity was defined by recorded diagnosis (gastroenteri-
tis, sepsis, respiratory infection etc). Maternal anaemia was more
consistently defined (Hb < 11.0 g/dl, Hb < 10.0 g/dl) but one
study fromMalawi reported change in Hb rather than percentage
of women not anaemic and thus we have not included it in the
meta-analysis.
The two largest studies fromNepal andGhana specifically assessed
the effect on maternal mortality with almost 95,000 women in-
cluded. The risk ratio (RR) of maternal mortality was found to be
0.78 (95% CI 0.55 to 1.1). Vitamin A deficiency is considered to
be endemic in Nepal and night blindness is commonly reported.
The main trial from Nepal by West 1999 reported a substantial
reduction in pregnancy-related mortality (including injuries) with
most of the mortality contributing to the difference between sup-
plementation and placebo groups occurring in death from injury,
chronic illness and uncertain cause of death which was difficult
to explain. The large study subsequently conducted in Ghana, a
country with moderate vitamin A deficiency, did not show an ef-
fect of vitamin A supplementation on maternal mortality.
Several trials specifically assessed the effect of vitamin A supple-
mentation during the antenatal period on maternal anaemia. Vi-
tamin A was given together with other micronutrients, principally
iron and folic acid. The Malawi study reported no effect of Vita-
min A in addition to iron supplementation on haemoglobin levels.
Assessment of Vitamin A status revealed the women were gener-
ally vitamin A replete. The other three studies were from countries
where vitamin A deficiency is considered to be endemic (Indone-
sia and Nepal) and from Tanzania, where the population studied
were all HIV-positive women. For the three studies included in
the meta-analysis, for a total of almost 2500 pregnant women,
maternal anaemia (Hb < 11.0g/dl) was found to be reduced with
a RR of 0.64 (95% CI 0.43 to 0.94).
Three studies measured maternal infection with a combined RR
of 0.37 (95%CI 0.18 to 0.77) after supplementation with vitamin
A in just under 1500 women studied. It was noted (as above)
that the criteria for the outcome ’infection’ varied between the
studies. The most significant study included in the meta-analysis
was conducted in the 1930s (Green 1931) and there are questions
related to the accuracy of the design of this study. Also it has not
been possible to calculate the exact dosage of Vitamin A given (in
the form of radiostoleum). In addition it must be noted that one
of the three studies was in HIV-positive women, who may have a
different overall risk of infection compared to non-HIV-positive
women.
No studies of supplementation in the antenatal period were specif-
ically designed to assess neonatal outcomes, but where these were
reportedwe have included them in the analyses. For studies report-
ing these outcomes, vitamin A supplementation does not affect
the risk of perinatal mortality (RR 1.01, 95% CI 0.95 to 1.07)
or stillbirth or neonatal mortality separately. Similarly, analysis of
available data shows no effect on preterm birth (RR 0.77, 95% CI
0.57 to 1.04) or low birthweight (RR 0.98, 95% CI 0.62 to1.54).
There were no reported side effects, adverse events or congenital
malformations in any of the trials.
The dose of vitamin A given, in combination with additional
micronutrients and the duration of supplementation differed in
the trials and varied between 5000 IU and 10,000 IU for daily
doses, around 200,000 IU vitamin A for weekly supplementation
and 200,000 IU vitamin A at time of delivery.
For one study supplementing vitamin A together with other mi-
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cronutrients (versus other micronutrients in control group) in
HIV-positive women, the risk of low birthweight was found to
reduced (RR 0.67, 95% CI 0.47 to 0.96).
There were no statistically significant differences in outcome for
any of the subgroup analyses performed.
Overall completeness and applicability of
evidence
The two cluster-randomised trials with a large number of partici-
pants were included in the meta-analysis and increased the accu-
racy and reliability of the evidence produced. Added to that, the
different populations studied by different included randomised
clinical trials amplified the applicability of the evidence produced.
Most of the specified outcomes were reported by some of the in-
cluded trials but the different trials were not designed to measure
the same primary outcomes and many of the specified secondary
outcomes were either not reported and/or defined differently in
the different country settings. The underlying baseline statistics
for maternal mortality, perinatal mortality and vitamin A status
of pregnant women were not available for the specific population
studies, and country estimates were therefore used in most cases.
Quality of the evidence
There was no lack of allocation concealment between the included
clinical trials; only three trials showed low concealment level.
Green 1931 and Suprapto 2002 used an alteration method for the
allocation generation and concealment; marking each first woman
as a participant and the next woman due to deliver as the control.
Suharno 1993 did not report how the allocation was generated or
concealed. In the case of blinding, all trials included were double
blinded except Ajans 1965 andGreen 1931, both of which did not
use any intervention in the control group. Four clinical trials in-
cluded lost more than 20% of the participants (Dijkhuizen 2004;
Kirkwood 2010; Radhika 2003; Semba 2001); these clinical trials
were conducted in rural areas with participants moving in and out
of the study area. None of the included trials were stopped early.
Accordingly, none of the included trials suffered any limitation at
the design or implementation level. Furthermore, all the included
trials directly compared the effects of vitamin A supplementation
on the mother and baby.
Heterogenity between trials in themeta-analysis was minimal (0%
to 40%). Added to that, the precision of the results can be consid-
ered good, with narrow confidence intervals in most cases except
for the subgroup analyses.
The underlying quality of methodology incorporated in the in-
cluded clinical trials as mentioned above and of the meta-analysis
mandate a general moderate to high quality rating of the body of
evidence based on the the GRADE approach used in this review.
For each outcome, the evidence could be rated. Analysis of RR for
preterm birth had a wide CI added to that; there were concerns
about the accuracy of assessment of gestational age, causing the
rating of the evidence to be low quality. For maternal anaemia
the evidence is strong and of high quality. In case of maternal
clinical infection,Green 1931 strongly influenced the pooled effect
estimate. Green 1931 was judged to be at risk of selection and
detection bias and there was concerns about the accuracy of the
measurement of infection in the studies; therefore, the evidence
for maternal clinical infection is of low quality.
For the use of vitaminAwith othermicronutrients versusmicronu-
trient supplements without vitamin A regarding maternal anaemia
outcome, results have a wide CI. Added to that, there was a high
risk of attrition bias in the three trials used for the comparison;
Semba 2001 excluded 32.5% of the participants from the analy-
sis, and Fawzi 1998 excluded 10.8%; in the case of Muslimatun
2001, 25.1% of the participants were lost for a variety of reasons.
Therefore, the rating of evidence for maternal anaemia for trials
using vitamin A with other micronutrients is considered to be of
low quality.
Potential biases in the review process
None known.
Agreements and disagreements with other
studies or reviews
The trials included in this review were carefully planned and exe-
cuted.
The absence of an effect on stillbirth rate, neonatal mortality,
or perinatal mortality accords with the findings of the two large
cluster trials (Cox 2005; Kirkwood 2010).
It has been suggested that vitamin A supplementation, especially
in the postpartum period, will reduce the incidence of sepsis. In
the trials reviewed, maternal clinical infection was assessed in a
number of ways and there is evidence to suggest that vitamin A
could have a significant effect on maternal infection. Maternal
anaemia evidence is of high quality with data to support that
supplementation with vitamin A reduces anaemia in vitamin A
deficient and HIV positive women.
There are no reports of side effects, adverse events or congenital
malformations in the trials published so far.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Overall the findings of this review do not currently support a role
for antenatal vitamin A supplementation to reduce maternal or
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perinatal mortality. There is, however, evidence that antenatal vita-
min A supplementation (in addition to iron and folic acid) reduces
maternal anaemia in populations that are vitamin A deficient and
inHIV-positive pregnant women. Although the available evidence
suggests a reduction in maternal infection when vitamin A is given
antenatally or around the time of delivery, the data are not of a
high quality and further evidence is needed to explore the effect of
antenatal vitamin A supplementation on maternal infection in the
antenatal and postnatal periods. The effect of vitamin A is likely
to depend on whether the population who receive supplements
are vitamin A deficient or not.
Implications for research
Results of 16 trials to assess effect of vitamin A supplementation
during pregnancy are presented in this review. The three main
outcomes examined are maternal mortality, maternal anaemia and
maternal infection.
It must be said that for any of these individual outcomes there
were between two and four trials that could be included in a meta-
analysis and even within this group of trials there was significant
difference in population with regard to Vitamin A status, baseline
anaemia and infection prevalence and maternal mortality ratio.
It seems unlikely that vitamin A supplementation per se con-
tributes directly to reducing maternal mortality. The evidence that
this might be possible originally came from the trial in Nepal
where vitamin A deficiency is common but reduction in deaths
was not in the category of direct maternal deaths. In Ghana it is
less likely women are vitamin A deficient and supplementation
did not reduce mortality. However, in this study there was a sub-
stantial number of women lost to follow-up. Both the Ghana and
Nepal trial results are in the same direction (a reduction in mater-
nal mortality). The trial from Ghana showed non-significant re-
sults. For this trial 43% of women migrated outside the study area
and 1% withdrew consent. These women contributed to the final
analysis either by completing a pregnancy before they migrated
or contributed data to the analysis of all-cause female mortality
by contributing person time to the denominator of this analysis.
Loss to follow up for pregnancy relatedmortality was subsequently
calculated to be 8% (supplementary information provided by au-
thors). For Nepal the reduction in deaths is difficult to explain
with biological plausibility, but it was a significant reduction. The
baseline vitamin A status in each of these trials was not assessed.
Vitamin A deficiency in Nepal is considered to be severe whereas
for Ghana this is considered to be moderate. For populations with
no or less deficiency in vitamin A , supplementation is likely to be
less effective.
It would seem that if any new trials are designed, it will be crucially
important to assess baseline vitamin A status as well as accurate
cause of maternal (and neonatal) death and to ensure follow-up
of women is possible. In resource-poor settings where maternal
mortality is highest and research most needed, this will also be
most difficult to ensure.
Further evidence on whether vitamin A can reduce infection in-
cluding maternal sepsis is needed.
To improve haemoglobin vitamin A supplementation in addition
to iron and folic acid is beneficial in women who are vitamin A
deficient or HIV-positive. The optimal dose of vitamin A, length
of supplementation and the maximum expected increase in hae-
moglobin have not been established. Also effect change will de-
pend on baseline degree of anaemia and vitamin A deficiency, and
this requires further study.
Itwas noted that there are differences between the trialswith regard
to the dose of vitamin A given, the combination with additional
micronutrients and the duration of supplementation. In addition,
baseline assessments of vitamin A status are often not available
even outside the study population, methods of assessment vary
and comparisons are therefore very difficult to make. For future
studies it is recommended that these are designed to take account
of these limitations. It would also be helpful if neonatal outcomes
are measured according to international criteria so that studies can
be compared.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ajans 1965
Methods RCT.
Participants Inclusion criteria: 44 parturient women in good health from the lower and middle
socioeconomic groups (in a population in which vitamin A deficiency occurs).
Interventions Intervention group1: 15 women.
Single intramuscular injection of 600,000 lU of vitamin A palmitate in oil at parturition.
4 samples of 2 to 3ml of colostrumwere collected. 1 antepartum sample and3postpartum
samples, 1 on each consecutive day of hospitalisation.
Intervention group 2: 11 women.
Given 600,000 lU of water-dispersible vitamin A palmitate orally shortly before delivery.
4 samples of 2 to 3ml of colostrumwere collected. 1 antepartum sample and3postpartum
samples, 1 on each consecutive day of hospitalisation. Followed by public health nurses
at their homes where bi-weekly samples of milk were collected during the first week after
discharge and then weekly samples for a total period ranging between 38 and 59 days
postpartum.
Control group:18 women not given any form of vitamin A therapy prepartum. Four
samples of 2 to 3ml of colostrumwere collected. 1 antepartum sample and 3 postpartum
samples, 1 on each consecutive day of hospitalisation.
Outcomes Primary outcome: levels of vit A and carotenoids in thematernal blood. Other outcomes:
levels of vit A and carotenoids in the colostrum prenatal and postnatal.
Notes Vit A levels measured before starting supplementation in group 1 and 2.
Study was done in a population in which vitamin A deficiency occurs.
Study setting: American university hospital.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No description except allotted at random.
Allocation concealment? Unclear No description except allotted at random.
Blinding?
All outcomes
No No placebo was used in this study.
Incomplete outcome data addressed?
All outcomes
Yes No exclusion or loss of follow up reported.
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
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Ajans 1965 (Continued)
Free of other bias? Yes
Coutsoudis 1999
Methods Double-blind RCT.
Participants Inclusion criteria:
• pregnant women 28-32 weeks’ gestation;
• HIV-positive.
(HIV-seropositive women identified through antenatal screening programmes. All the
women enrolled were black Africans.)
Interventions Intervention group: 368 women received daily dose of 5000 IU retinyl palmitate and
30 mg beta-carotene during the third trimester of pregnancy (together corresponding to
43,400 IU vit A daily for 12 weeks) and 200,000 IU retinyl palmitate at delivery.
Control group: 360 women received placebo on the same schedule.
Outcomes Primary outcome: effects of vit A on HIV viral load and HIV transmission.
Other outcomes: neonatal mortality (the number of deaths during the first 28 completed
days of life per 1000 live births in a given year or period) and anaemia, maternal anaemia,
clinical infection (fever > 1 week at 1 week postnatally), preterm birth (delivery less
than 37 completed weeks’ gestational age estimated using LMP) , low birth weight and
morbidity.
Notes Vit A levels were measured before starting supplementation.
Country: South Africa.
Study setting: King Edward VIII Hospital and McCords Hospital, in Durban, South
Africa
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
Yes 57 (7.8%) women did not deliver in the hospitals and cannot
be traced.
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
Free of other bias? Yes
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Cox 2005
Methods A randomised double-blind controlled trial.
Participants Inclusion criteria:
• primigravid pregnant women;
• resident within the study area;
• in good health;
• less than 24 weeks pregnant.
Exclusion criteria: HIV infection or tuberculosis.
Interventions Intervention group: 48 women received weekly capsules of 10,000 IU of vitamin A as
retinyl palmitate in groundnut oil, plus tocopherol as a preservative from enrolment
until 6 weeks postpartum. Suplimintation was for a minimum of 18 weeks.
Control group: 50 women received groundnut oil and tocopherol only in the placebo
capsules from enrolment until 6 weeks postpartum.
Outcomes Primary outcome: maternal infections (presence of placental malaria and peripheral
parasitaemia).
Other outcomes: haemoglobin and birth weight.
Notes Vit A levels were measured before starting supplementation.
Country: Ghana.
Study setting: Nkoranza District Hospital and three rural health clinics in Brong Ahafo
region, Central Ghana.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “balanced block randomisation.”
Allocation concealment? Unclear No information provided.
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
Yes 12 (12%) women were excluded from the
analysis: 1 false pregnancy, 1 early miscar-
riage, 10 missed late pregnancy visit.
Free of selective reporting? Unclear The protocol of the study is not available
at the moment.
Free of other bias? Unclear The most marked difference was in edu-
cational level and gestational age at enrol-
ment. Levels of anti-VSACSA IgG to the
FCR3CSA parasite line differed between
the treatment groups at baseline. There
were considerably fewer data available for
the placebo than the vitamin A group at the
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Cox 2005 (Continued)
late pregnancy follow-up.
Dijkhuizen 2004
Methods Double-blind RCT, factorial design.
Participants Inclusion criteria: all women were recruited before 20 weeks’ gestational age.
Exclusion criteria: twin pregnancy and congenital abnormalities that interfered with
growth, development, or metabolism.
Interventions Intervention group 1: 37 women received iron and folic acid supplements together with
ß -carotene (4.5 mg as water-soluble granulate/d (representing 5750 IU of vit A)). Each
woman was supplemented daily during pregnancy until delivery for a minimum of 16
weeks.
Intervention group 2: 37 women received iron and folic acid supplements together with
zinc (30 mg zinc as sulfate/d). Each woman was supplemented daily during pregnancy
until delivery.
Intervention group 3: 37 women received iron and folic acid supplements together with
zinc and carotene. Each woman was supplemented daily during pregnancy until delivery.
Control group: 37 women received iron and folic acid.
Outcomes Primary outcome: maternal and fetal haemoglobin and zinc levels.
Other outcomes: maternal and fetal ferritin, retinol and carotene levels.
Notes Vit A levels were not measured before starting supplementation.
Country: Indonesia.
Study setting:13 adjacent villages in a rural area in Bogor District, West Java, Indonesia.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided except factorial ran-
domisation.
Allocation concealment? Yes “Capsules were indistinguishable and given a let-
ter code.”
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
No 51 (22.2%) women were not included in the
analyses.
Free of selective reporting? Unclear The protocol of the study is not available at the
moment.
Free of other bias? Yes
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Fawzi 1998
Methods 2-by-2 factorial design.
Participants Inclusion criteria:
• pregnant women 12-27 weeks’ gestation;.
• HIV-positive women;
• resident in Dar es Salaam at the time of baseline interview;
• intend to stay in the city until delivery and 1 year breastfeeding thereafter.
Interventions Intervention group 1: 270 women received a daily (for at least 10 weeks) oral dose of
multivitamins including vitamin A (30 mg b-carotene (representing 38,000 IU vit A)
and 5000 IU of preformed vitamin A, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg
of niacin, 50 mg of B12, 500 mg of C, 30 mg of vitamin E, and 0.8 mg of folic acid);
an additional oral dose of vitamin A (200,000 IU) at delivery.
Intervention group 2: 269 women received a daily oral dose of vitamin A alone (30 mg
b-carotene and 5000 IU of preformed vitamin A), plus an additional oral dose of vitamin
A (200,000 IU) at delivery.
Intervention group 3: 269 women received a daily oral dose of multivitamins excluding
vitamin A, plus an additional oral placebo at delivery.
Intervention group 4: 267 women received a daily oral dose of placebo. An additional
oral placebo at delivery.
Outcomes Primary outcome: CD levels in both mother and fetus and HIV transmission.
Other outcomes: birth weight, preterm birth (delivery less than 37 completed weeks
estimated using LMP) and haemoglobin in both mother and fetus (Hb < 10.0 g/dl).
Notes Vit A levels were measured before starting supplementation.
Country: Tanzania.
Study setting: four antenatal clinics with several smaller peripheral clinics.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomisation was done in blocks of 20.”
Allocation concealment? Yes “At enrolment, we assigned each eligiblewomen the next num-
bered bottle of regimen.”
Blinding?
All outcomes
Yes Double blind.
Incomplete outcome data addressed?
All outcomes
Yes 117 (10.8%) women were excluded from the analysis:
• 3 not pregnant;
• 7 died before delivery and excluded;
• 54 lost to follow-up;
• 53 no date of delivery or gestational age.
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
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Fawzi 1998 (Continued)
Free of other bias? Yes
Green 1931
Methods Quasi-RCT, multi-centred.
Participants Inclusion criteria: pregnant women.
Exclusion criteria: cases not delivered in hospital.
Interventions Intervention group: 275 women received 1 oz of the vitamin preparation radiostoleum,
an amount equivalent in vitamins A and D roughly to 30 oz of a good cod-liver oil
(equivalent to 444,000 IU vit A) , should have been taken daily commencing one month
previous to the calculated day of labour.
The first 76 cases prior to June 1929 were given the preparation for only 14 days before
delivery (daily). It was, however, continued for the first seven days of the puerperium.
It was then decided that a more logical procedure would probably be to begin the
administration earlier and thus build up a larger reserve at the time of labour.
Control group:275 women received an untreated version.
Outcomes Maternal infection (puerperal fever > 38o C) and maternal and baby mortality and
morbidity.
Notes Vit A levels were not measured before starting supplementation.
Country: UK.
Study setting: the Jessop Hospital and the Nether Edge municipal hospital.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No “the first patient was given the preparation and the next
due for delivery about the same time was indexed as a
control.”
Allocation concealment? No “the first patient was given the preparation and the next
due for delivery about the same time was indexed as a
control.”
Blinding?
All outcomes
No The control group received no intervention.
Incomplete outcome data addressed?
All outcomes
Yes 50 (8.3%) women delivered somewhere else and were ex-
cluded.
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
Free of other bias? Yes
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Kirkwood 2010
Methods Cluster-randomised trial.
Participants Inclusion criteria: women aged 15 to 45 years giving informed consent and who planned
to live in the trial area for at least 3 months were eligible for enrolment.
Interventions Intervention group: 104,484 women in 544 clusters received weekly vitamin A capsule
consisted of 25,000 IU (7500 ug) retinol equivalents (equivalent to 25,000 IU vit A) in
soybean oil in a dark red opaque soft gel for 12 weeks.
Control group: 103,297 women in 542 clusters received placebo capsule consisted of
soybean oil only.
Outcomes Primary outcome: maternal mortality and all-cause female mortality.
Other outcomes: maternal morbidity, perinatal and neonatal mortality (the number of
deaths during the first 28 completed days of life per 1000 live births in a given year or
period).
Notes Vit A levels were not measured before starting supplementation.
Country: Ghana.
Study setting: rural districts in Brong Ahafo Region in Ghana.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “A computer-generated randomisation list.”
Allocation concealment? Yes “The capsules were packaged in labelled jars.”
Blinding?
All outcomes
Yes Double blind.
Incomplete outcome data addressed?
All outcomes
Yes 44% of enrolled women initially reported as loss to follow
up: 1% withdrew consent, 43% moved. However, supple-
mentary information provided by authors in February 2011
at the time of more detailed analysis reported overall loss to
follow up for analysis for pregnancy-related mortality analy-
sis as 8%: 4657 pregnancies excluded because outcome not
known (with 2340 in vitamin A arm and 2317 in placebo
arm). 4192 pregnancies excluded because status of woman
at 42 days not known (2174 Vitamin A; 2018 placebo). Be-
fore these exclusions, the total number of pregnancies cap-
tured was 111,801; after exclusions, the total number of
pregnancies with a known outcome was 102,952.
Free of selective reporting? Yes
Free of other bias? Yes
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Kumwenda 2002
Methods RCT.
Participants Inclusion criteria:
• pregnant women of 18-28 weeks’ gestation;
• HIV-positive women.
Interventions Intervention group: 340 women received daily doses of orally administered vitamin A (3
mg retinol equivalent (10,000 IU of vit A) + iron and folate for minimum of 12 weeks.
Oral vitamin A (30 mg retinol equivalent) at 6 weeks’ postpartum
Control group: 357 women received daily doses of iron (30 mg of elemental iron) and
folate (400 mg) from the time of study enrolment until delivery. Oral vitamin A (30 mg
retinol equivalent) at 6 weeks postpartum.
Outcomes Primary outcome: maternal vit A levels in blood and breast milk and HIV transmission
in mother and baby.
Other outcomes: haemoglobin and birth weight.
Notes Vit A levels were measured before starting supplementation.
Country: Malawi.
Study setting: Queen Elizabeth Central Hospital (Blantyre, Malawi).
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “a computer random-number generator.”
Allocation concealment? Yes “prepacking study supplements in sequentially numbered series
assigned to study identification numbers.”
Blinding?
All outcomes
Yes Double blind.
Incomplete outcome data addressed?
All outcomes
Yes 63 (9%) women were excluded from the analysis: 57 moved out,
6 could not be located.
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
Free of other bias? Yes
Muslimatun 2001
Methods A randomised double-blind community-based trial.
Participants Inclusion criteria: 16 to 20 weeks pregnant, aged 17-35 years and parity < 6.
Interventions Intervention group: 122 women received each week from enrolment until delivery two
tablets each of which contained 3000 RE vitamin A in addition to the ferrous sulfate and
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Muslimatun 2001 (Continued)
folic acid. So intervention was 6000 RE vitamin A (20,000 IU) weekly for a minimum
of 16 weeks.
Control group: 121 women received each week from enrolment until delivery two tablets
each containing 60 mg elemental iron as ferrous sulfate and 250 mg folic acid.
Outcomes Primary outcome: infant growth in y 1 of life.
Other outcomes: maternal haemoglobin and fetal morbidity.
Notes Vit A levels were measured before starting supplementation.
Country: Indonesia.
Study setting: 9 villages in the rural subdistrict of Leuwiliang, West Java, Indonesia.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Assigned randomly.”
Allocation concealment? Unclear No information provided.
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
No Out of 243 pregnant women initially en-
rolled, 18 dropped out during pregnancy, 5
gave birth to a stillborn child, 1 had twins
(only 1 survived), 7 had infants who died
before reaching 3 months of age and 11
moved from the research area. Among the
remaining 201 eligible participants, 182
participants attended the postpartum ex-
amination.
Free of selective reporting? Unclear The protocol of the study is not available
at the moment.
Free of other bias? Yes
Radhika 2003
Methods “double-blinded, randomized, controlled study.”
Participants Inclusion criteria:
• 16 and 24 weeks’ gestation;
• willing to have a follow up every 2 weeks and who resided in the city area were
chosen for the study.
Exclusion criteria: women with recurrent pregnancy loss or earlier preterm delivery and
those with diabetes, hypertension, or any other metabolic disorder.
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Radhika 2003 (Continued)
Interventions Intervention group: 85 women received red palm oil providing 2173 to 2307 µg of β-
carotene per day with a dosage schedule of one sachet per day (8 ml), which provided
91% to 96% of the daily requirement of vitamin A in pregnancy, (i.e., 2400 µg of β-
carotene which is equivalent to 3000 IU of vit A) daily for a period of 8 weeks.
Control group: 85 women received one sachet of groundnut oil (8 ml) for a period of 8
weeks.
Outcomes Primary outcome: maternal and neonatal vitamin A status.
Other outcomes: haemoglobin levels in mother and baby, preterm birth (delivery less
than 37 completed weeks as confirmed by ultrasound examination), birthweight and
gestational age.
Notes Vit A levels were measured before starting supplementation.
Country: India.
Study setting: the outpatient department of Niloufer Hospital, Hyderabad, India.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
No 41 (24.1%)womenwere excluded from the
analysis: 23 were not available for supple-
mentation, while 18 dropped out after ini-
tiating supplementation.
Free of selective reporting? Unclear The protocol of the study is not available
at the moment.
Free of other bias? Yes
Semba 2001
Methods A randomised, double-blind, controlled clinical trial.
Participants Inclusion criteria:
• pregnant women;
• 18-28 weeks’ gestation;
• HIV-negative women.
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Semba 2001 (Continued)
Interventions Intervention group: 109 women received daily supplement containing iron (30 mg
elemental iron), folate (400 mg), and vitamin A (3000 µg retinol equivalent, which is
10,000 IU of vit A) until delivery for a minimum of 8 weeks.
Control group: 94 women received daily supplement containing iron (30 mg) and folate
(400 mg) until delivery.
Outcomes Primary outcome: haemoglobin concentrations and plasma erythropoietin concentra-
tions.
Other outcomes: levels of ferritin, ?1-acid glycoprotein, C-reactive protein and plasma
vitamin A.
Notes Vit A levels were measured before starting supplementation.
Country: Malawi.
Study setting: the Queen Elizabeth Central Hospital in Blantyre, Malawi.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “a computer random-number generator.”
Allocation concealment? Yes “sequentially numbered opaque bottle.”
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
No 66 (32.5%)womenwere excluded from the
analysis: 42 missed the study visit, 9 did
not have their haemoglobin analysed, 15
moved out.
Free of selective reporting? Unclear The protocol of the study is not available
at the moment.
Free of other bias? Yes
Suharno 1993
Methods Double-blinded RCT.
Participants Inclusion criteria:
• middle and low socioeconomic;
• 16-24 weeks pregnant;
• 17-35 years old;
• parity 0-4;
• haemoglobin 80-109 g/l.
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Suharno 1993 (Continued)
Interventions Intervention group 1: 63 women received vitamin A (2.4 mg retinol as retinyl palmitate)
(equivalent to 8000 IU of vit A) and placebo iron tablets daily for 8 weeks.
Intervention group 2: 63 women received iron tablets (60 mg ferrous sulphate) and
placebo vitamin A daily for 8 weeks.
Intervention group 3: 63 women received vitamin A and iron daily for 8 weeks.
Control group: 62 women received both placebo daily for 8 weeks.
Outcomes Maternal anaemia indices.
Notes Vit A levels were measured before starting supplementation.
Country: Indonesia.
Study setting: rural villages in 3 subdistricts of Bogo, West Java.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “randomly.”
Allocation concealment? No
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
Yes 54 (17%) women were excluded from the analysis: 11 moved,
23 taken supplement less than 8 weeks, 10 refused blood sam-
ple, 10 not available for 2nd blood sample.
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
Free of other bias? Yes
Suprapto 2002
Methods Quasi-RCT. A double-blind, placebo, controlled trial.
Participants Inclusion criteria:
• aged less than 35 years;
• between 13 and 28 weeks’ gestation;
• single pregnancy;
• in good health;
• anaemia (haemoglobin < 11.0 g/dL).
Exclusion criteria:
• pregnant women with pre-eclampsia, congestive heart disease, tuberculosis and
acute infections;
• women in the first trimester of pregnancy.
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Suprapto 2002 (Continued)
Interventions Intervention group 1: 22women; group IFR received iron-folate tablets + 5mg riboflavin
seven days a week for 60 days.
Intervention group 2: 29 women; group IFA received iron-folate tablets + 2.75mg retinyl
palmitate (equal to 5000 IU vitamin A) seven days a week for 60 days.
Intervention group 3: 23 women; group IFRA received iron-folate tablets + 5 mg ri-
boflavin + 2.75 mg retinyl palmitate seven days a week for 60 days.
Control group: 29 women; group IF received iron-folate tablets + 5 mg glucose seven
days a week for 60 days.
Outcomes Maternal levels of vitamin A and riboflavin.
Notes Vit A levels were measured before starting supplementation.
Country: Indonesia.
Study setting: health centre antenatal clinic.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No “allocated alternately.”
Allocation concealment? No “allocated alternately.”
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
Yes 19 (18.4%) were excluded from the analy-
ses: 9 premature labour, 1 stillbirth, 1 mi-
gration, 1 refusal to give blood, 2 nausea
and vomiting and 5 incorrect dates given
for last menstruation but with normal de-
liveries.
Free of selective reporting? Unclear The protocol of the study is not available
at the moment.
Free of other bias? No Women in group IFRA were shorter and
lighter than those in other groups.
Tanumihardjo 2002
Methods RCT.
Participants Inclusion criteria:
• pregnant women in the second or early third trimester;
• 18 to 37 years old;
• parity from 0 to 4 children.
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Tanumihardjo 2002 (Continued)
Interventions Intervention group 1: 5 women received 1.07 mmol (60 mg) ferrous sulfate with a
vitamin A placebo daily for 8 weeks.
Intervention group 2: 8 women received vitamin A plus iron.
Intervention group 3: 7 women received 8.4 µmol (8000 IU) vitamin A as retinyl palmi-
tate with an iron placebo.
Control group: 7 women received placebo.
Outcomes Maternal haemoglobin and retinol levels.
Notes Vit A levels were measured before starting supplementation.
Country: Indonesia.
Study setting: local health posts the suburban areas of Bogor in West Java.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information provided.
Allocation concealment? Unclear No information provided.
Blinding?
All outcomes
Yes “Subjects and village volunteers (caders) were unaware of group
assignment.”
Incomplete outcome data addressed?
All outcomes
Yes
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
Free of other bias? Unclear Not enough information provided.
van den Broek 2006
Methods RCT.
Participants Inclusion criteria:
• (Hb) < 11.0 g/dl by HemoCue screening method at first antenatal visit;
• singleton pregnancy with gestational age > 12 weeks and < 24 weeks measured by
ultrasound scan;
• no fetal abnormality detectable by ultrasound at time of booking;
• residing in the catchment area of the health centre;
• signed informed consent.
Exclusion criteria: twin pregnancy.
Interventions Intervention group 1: 234 women; 5000 IU vitamin A and iron tablets daily (60 mg
elemental iron as ferrous sulphate with 0.25 mg folic acid) and antimalarial prophylaxis
as two doses of Fansidar (500 mg sulphadoxine with 25 mg pyrimethamine. Tablets
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van den Broek 2006 (Continued)
given daily from enrolment till delivery minimum of 8 weeks.
Intervention group 2: 234 women; 10,000 IU vitamin A and iron tablets daily (60 mg
elemental iron as ferrous sulphate with 0.25 mg folic acid) and antimalarial prophylaxis
as two doses of Fansidar (500 mg sulphadoxine with 25 mg pyrimethamine).
Control group: 232 women; placebo and iron tablets daily (60 mg elemental iron as
ferrous sulphate with 0.25 mg folic acid) and antimalarial prophylaxis as two doses of
Fansidar (500 mg sulphadoxine with 25 mg pyrimethamine.
Outcomes Primary outcome: haemoglobin concentrations and anaemia.
Other outcomes: iron status, preterm birth (delivery less than 37 completed weeks as
confirmed by ultrasound examination),markers of infections includedC-reactive protein
(CRP), malaria parasitaemia and HIV status.
Notes Vit A levels were measured before starting supplementation.
Country: Malawi.
Study setting: rural southern Malawi attending ANC at Health Centres.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “a random-generation procedure.”
Allocation concealment? Yes “consecutive numbers” “in sealed envelopes.”
Blinding?
All outcomes
Yes
Incomplete outcome data addressed?
All outcomes
Yes 96 (13.7%) women were excluded from the analyses: 18 women
moved out from the area, 68 declined to continue, 10 missed
appointment.
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
Free of other bias? Yes
West 1999
Methods Double-blind cluster RCT.
Participants Inclusion criteria:
• women of childbearing age who were married and living with their husbands;
• newly married women.
Exclusion criteria: women who were already married who had moved into study wards.
Interventions Intervention group 1: 15,305 women in 90 wards received opaque, gelatinous capsules
containing peanut oil and 23,300 IU of preformed vitamin A (7000 µg retinol equiva-
lents) as retinyl palmitate weekly for a minimum of 12 weeks.
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West 1999 (Continued)
Intervention group 2: 14,536 women in 90 wards received 42 mg of all trans-b carotene
(7000 µg retinol equivalents, assuming a conversion ratio to retinol of 6 to 1 after uptake)
weekly.
Control group: 14,805 women in 90 wards received no vitamin A or b carotene (placebo)
weekly.
Outcomes Primary outcome: mortality of mother and baby (the number of deaths during the first
28 completed days of life per 1000 live births in a given year or period).
Other outcomes: maternal vit A and retinol levels, and maternal morbidity.
Notes Vit A levels were not measured before starting supplementation.
Country: Nepal.
Study setting: 270 wards in 30 subdistricts.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “All wards were assigned in Kathmandu by a random
draw of numbered chits, blocked on subdistrict, for eligi-
ble women to receive one of three identical coded supple-
ments.”
Allocation concealment? Yes “’three identical coded supplements.”
Blinding?
All outcomes
Yes “double-blind.”
Incomplete outcome data addressed?
All outcomes
Yes 1136 (2.5%) women were excluded because they emi-
grated before becoming pregnant or dying or because they
declined to be recruited. 157 women were lost to follow-
up during the postpartum period (their median follow-up
time postpartum was around 2 weeks in each group.
Free of selective reporting? Unclear The protocol of the study is not available at the moment.
Free of other bias? Yes
ANC: antenatal clinic
CRP: C-reactive protein
IU: international unit
RCT: randomised controlled trial
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Banerjee 2009 Intervention uses lycopene which is a compound that lacks beta-ion ring (in the β-carotene), so lycopene cannot
form vitamin A and its biological effects are due to mechanism other than forming vitamin A.
Chawla 1995 Not a randomised trial.
Chikobvu 2001 Double blind randomised trial with outcomes on HIV transmission and HIV complications, only abstract
available.
Christian 2003 Cluster-randomised trial with all arms of intervention containing vitamin A and no comparison for vitamin A.
Darboe 2007 Intervention started after delivery.
Haskell 2005 Both arms of intervention containing vitamin A and no comparison for vitamin A.
Howells 1986 Not a randomised trial.
Humphrey 2006 Intervention started after delivery.
Laitinen 2009 Not a randomised trial and vitamin A present in both arms of intervention.
Lietz 2001 Both arms of intervention containing vitamin A and no comparison for vitamin A.
Roberfroid 2010 Both arms of intervention containing iron and folic acid and no comparison for vitamin A.
Roy 1997 Intervention started after delivery.
Sharma 2003 Intervention uses lycopene which is a compound that lacks beta-ion ring (in the β-carotene), so lycopene cannot
form vitamin A and its biological effects are due to mechanism other than forming vitamin A.
Van Vliet 2001 Participants are non-pregnant women.
Characteristics of studies awaiting assessment [ordered by study ID]
Hakimi 1999
Methods No information provided.
Participants Women with positive pregnancy test in the first 120 days of pregnancy.
Interventions Group received vitamin A 2400 retinol equivalent, second group received zinc 20 mg/day, third group received both
vitamin A and zinc, while the fourth group received placebo.
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Hakimi 1999 (Continued)
Outcomes Maternal sepsis (temp 38oC between day 2-14 postpartum), haemorrhage (bleeding during labour or within 2
days of delivery).
Notes Trial run between 1995 and 1997 in Indonesia.
49Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Vitamin A alone versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 3 Risk Ratio (Random, 95% CI) 0.78 [0.55, 1.10]
2 Perinatal mortality 1 Risk Ratio (Fixed, 95% CI) 1.01 [0.95, 1.07]
3 Neonatal mortality 3 Risk Ratio (Fixed, 95% CI) 0.97 [0.90, 1.05]
4 Stillbirth 1 78835 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.98, 1.14]
5 Maternal anaemia 3 Risk Ratio (Random, 95% CI) 0.64 [0.43, 0.94]
6 Maternal clinical infection 3 Risk Ratio (Random, 95% CI) 0.37 [0.18, 0.77]
7 Maternal night blindness 1 Risk Ratio (Fixed, 95% CI) 0.70 [0.60, 0.82]
8 Preterm birth 4 1937 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.57, 1.04]
9 Neonatal anaemia 1 406 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.92, 1.08]
10 Neonatal clinical infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Congenital malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12 Low birthweight 3 890 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.62, 1.54]
Comparison 2. Vitamin A alone versus micronutrient supplement without vitamin A
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Perinatal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 Neonatal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Stillbirth 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Maternal anaemia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Maternal clinical infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Maternal night blindness 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Preterm birth 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Neonatal anaemia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Neonatal clinical infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Congenital malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12 Low birthweight 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Comparison 3. Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Perinatal mortality 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 Neonatal mortality 1 594 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.32, 1.31]
4 Stillbirth 2 866 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.57, 3.47]
5 Maternal anaemia 3 706 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.68, 1.09]
6 Maternal clinical infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Maternal night blindness 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Preterm birth 1 136 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.08, 1.93]
9 Neonatal anaemia 2 1052 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.38, 1.51]
10 Neonatal clinical infection 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Congenital malformations 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12 Low birthweight 1 594 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.47, 0.96]
Comparison 4. Vitamin A alone versus placebo or no treatment (subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality (infant
mortality level)
3 Risk Ratio (Random, 95% CI) 0.78 [0.55, 1.10]
1.1 Countries with low infant
mortality
1 Risk Ratio (Random, 95% CI) 0.33 [0.01, 9.44]
1.2 Countries with high infant
mortality
2 Risk Ratio (Random, 95% CI) 0.77 [0.51, 1.17]
2 Perinatal mortality (infant
mortality level)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
2.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 Countries with high infant
mortality
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
3 Maternal mortality (maternal
mortality level)
3 101574 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.01]
3.1 Countries with low
maternal mortality
1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.15]
3.2 Countries with high
maternal mortality
2 101024 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
4 Perinatal mortality (maternal
mortality level)
1 73743 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.88, 1.03]
4.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 Countries with high
maternal mortality
1 73743 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.88, 1.03]
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5 Maternal mortality (prevalence
of vitamin A deficiency)
3 101574 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.01]
5.1 Low prevalence of vitamin
A deficiency
1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.15]
5.2 High prevalence of
vitamin A deficiency
2 101024 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
6 Perinatal mortality (prevalence
of vitamin A deficiency)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
6.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 High prevalence of
vitamin A deficiency
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
7 Maternal mortality (prevalence
of HIV in the general
population)
3 101574 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.01]
7.1 Countries with low HIV
prevalence
3 101574 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.01]
7.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Perinatal mortality (prevalence of
HIV in the general population)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
8.1 Countries with low HIV
prevalence
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
8.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Maternal mortality (dose) 2 101024 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
9.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9.2 Others 2 101024 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
10 Perinatal mortality (dose) 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
10.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10.2 Others 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
11 Maternal mortality (regimen) 3 101574 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.01]
11.1 Daily 1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.15]
11.2 Weekly 2 101024 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
11.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12 Perinatal mortality (regimen) 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
12.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.2 Weekly 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
12.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
13 Maternal mortality (duration
of intervention)
1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.15]
13.1 One month or less 1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.15]
14 Perinatal mortality (duration of
intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15 Maternal mortality (trimester
of pregnancy)
3 101574 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.01]
15.1 Pre-pregnancy 2 101024 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
15.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.4 Third trimester 1 550 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.15]
15.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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16 Perinatal mortality (trimester
of pregnancy)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
16.1 Pre-pregnancy 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
16.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17 Maternal mortality
(randomisation)
2 101024 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
17.1 Cluster-randomised 2 101024 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.68, 1.02]
17.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18 Perinatal mortality
(randomisation)
1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
18.1 Cluster-randomised 1 76176 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.95, 1.07]
18.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 5. Vitamin A alone versus micronutrient supplement without vitamin A (subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality (infant
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 Countries with high infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Perinatal mortality (infant
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 Countries with high infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 Maternal mortality (maternal
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.2 Countries with high
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Perinatal mortality (maternal
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 Countries with high
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Maternal mortality (prevalence
of vitamin A deficiency)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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5.2 High prevalence of
vitamin A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Perinatal mortality (prevalence
of vitamin A deficiency)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 High prevalence of
vitamin A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Maternal mortality (prevalence
of HIV in the general
population)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.1 Countries with low HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Perinatal mortality (prevalence of
HIV in the general population)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.1 Countries with low HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Maternal mortality (dose) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9.2 Others 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Perinatal mortality (dose) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10.2 Others 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Maternal mortality (regimen) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11.2 Weekly 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12 Perinatal mortality (regimen) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.2 Weekly 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
13 Maternal mortality (duration
of intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14 Perinatal mortality (duration of
intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15 Maternal mortality (trimester
of pregnancy)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.1 Pre-pregnancy 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16 Perinatal mortality (trimester
of pregnancy)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.1 Pre-pregnancy 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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16.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17 Maternal mortality
(randomisation)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17.1 Cluster-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18 Perinatal mortality
(randomisation)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18.1 Cluster-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 6. Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
(subgroups)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal mortality (infant
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 Countries with high infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Perinatal mortality (infant
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.1 Countries with low infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 Countries with high infant
mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 Maternal mortality (maternal
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.2 Countries with high
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Perinatal mortality (maternal
mortality level)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.1 Countries with low
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 Countries with high
maternal mortality
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Maternal mortality (prevalence
of vitamin A deficiency)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 High prevalence of
vitamin A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Perinatal mortality (prevalence
of vitamin A deficiency)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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6.1 Low prevalence of vitamin
A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 High prevalence of
vitamin A deficiency
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Maternal mortality (prevalence
of HIV in the general
population)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.1 Countries with low HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Perinatal mortality (prevalence of
HIV in the general population)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.1 Countries with low HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.2 Countries with high HIV
prevalence
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Maternal mortality (dose) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9.2 Others 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Perinatal mortality (dose) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10.1 Daily 10,000 IU 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10.2 Others 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Maternal mortality (regimen) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11.2 Weekly 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12 Perinatal mortality (regimen) 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.1 Daily 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.2 Weekly 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12.3 Other regimen 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
13 Maternal mortality (duration
of intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14 Perinatal mortality (duration of
intervention)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15 Maternal mortality (trimester
of pregnancy)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.1 Pre-pregnancy 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
15.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16 Perinatal mortality (trimester
of pregnancy)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.1 Pre-pregnancy 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.2 First trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.3 Second trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.4 Third trimester 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
16.5 Mixed 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17 Maternal mortality
(randomisation)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17.1 Cluster-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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17.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18 Perinatal mortality
(randomisation)
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18.1 Cluster-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18.2 Individual-randomised 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Analysis 1.1. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 1 Maternal
mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 1 Maternal mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Green 1931 -1.10866 (1.711246) 1.1 % 0.33 [ 0.01, 9.44 ]
Kirkwood 2010 -0.08338 (0.120335) 61.9 % 0.92 [ 0.73, 1.16 ]
West 1999 -0.51083 (0.221012) 37.0 % 0.60 [ 0.39, 0.93 ]
Total (95% CI) 100.0 % 0.78 [ 0.55, 1.10 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 3.18, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 1.42 (P = 0.16)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.2. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 2 Perinatal
mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 2 Perinatal mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Kirkwood 2010 0.00995 (0.030345) 100.0 % 1.01 [ 0.95, 1.07 ]
Total (95% CI) 100.0 % 1.01 [ 0.95, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.3. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 3 Neonatal
mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 3 Neonatal mortality
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Coutsoudis 1999 -0.34249 (0.474682) 0.7 % 0.71 [ 0.28, 1.80 ]
Kirkwood 2010 -0.05129 (0.043067) 81.0 % 0.95 [ 0.87, 1.03 ]
West 1999 0.09531 (0.090425) 18.4 % 1.10 [ 0.92, 1.31 ]
Total (95% CI) 100.0 % 0.97 [ 0.90, 1.05 ]
Heterogeneity: Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.68 (P = 0.50)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.4. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 4 Stillbirth.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 4 Stillbirth
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kirkwood 2010 1249/39512 1175/39323 100.0 % 1.06 [ 0.98, 1.14 ]
Total (95% CI) 39512 39323 100.0 % 1.06 [ 0.98, 1.14 ]
Total events: 1249 (Vit A), 1175 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.5. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 5 Maternal anaemia.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 5 Maternal anaemia
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Fawzi 1998 -0.17435 (0.255778) 27.7 % 0.84 [ 0.51, 1.39 ]
Suharno 1993 -0.96758 (0.261069) 27.2 % 0.38 [ 0.23, 0.63 ]
West 1999 -0.31471 (0.090425) 45.2 % 0.73 [ 0.61, 0.87 ]
Total (95% CI) 100.0 % 0.64 [ 0.43, 0.94 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 6.19, df = 2 (P = 0.05); I2 =68%
Test for overall effect: Z = 2.24 (P = 0.025)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.6. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 6 Maternal clinical
infection.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 6 Maternal clinical infection
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Coutsoudis 1999 -0.56212 (0.748015) 19.0 % 0.57 [ 0.13, 2.47 ]
Green 1931 -0.77653 (0.200388) 61.5 % 0.46 [ 0.31, 0.68 ]
West 1999 -2.12026 (0.735802) 19.5 % 0.12 [ 0.03, 0.51 ]
Total (95% CI) 100.0 % 0.37 [ 0.18, 0.77 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 3.26, df = 2 (P = 0.20); I2 =39%
Test for overall effect: Z = 2.64 (P = 0.0083)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.7. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 7 Maternal night
blindness.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 7 Maternal night blindness
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
West 1999 -0.35677 (0.078366) 100.0 % 0.70 [ 0.60, 0.82 ]
Total (95% CI) 100.0 % 0.70 [ 0.60, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.55 (P < 0.00001)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.8. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 8 Preterm birth.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 8 Preterm birth
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Coutsoudis 1999 38/335 57/326 66.3 % 0.65 [ 0.44, 0.95 ]
Green 1931 1/275 0/275 0.6 % 3.00 [ 0.12, 73.32 ]
Radhika 2003 9/64 11/58 13.3 % 0.74 [ 0.33, 1.66 ]
van den Broek 2006 29/401 13/203 19.8 % 1.13 [ 0.60, 2.12 ]
Total (95% CI) 1075 862 100.0 % 0.77 [ 0.57, 1.04 ]
Total events: 77 (Vit A), 81 (Placebo or no treatment)
Heterogeneity: Chi2 = 2.89, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.9. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 9 Neonatal anaemia.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 9 Neonatal anaemia
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fawzi 1998 177/209 168/197 100.0 % 0.99 [ 0.92, 1.08 ]
Total (95% CI) 209 197 100.0 % 0.99 [ 0.92, 1.08 ]
Total events: 177 (Vit A), 168 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.12. Comparison 1 Vitamin A alone versus placebo or no treatment, Outcome 12 Low
birthweight.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 1 Vitamin A alone versus placebo or no treatment
Outcome: 12 Low birthweight
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Coutsoudis 1999 42/346 48/343 55.8 % 0.87 [ 0.59, 1.28 ]
Cox 2005 11/41 5/38 18.2 % 2.04 [ 0.78, 5.33 ]
Radhika 2003 10/64 12/58 26.0 % 0.76 [ 0.35, 1.62 ]
Total (95% CI) 451 439 100.0 % 0.98 [ 0.62, 1.54 ]
Total events: 63 (Vit A), 65 (Placebo or no treatment)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.98, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 0.10 (P = 0.92)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 3.3. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 3 Neonatal mortality.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 3 Neonatal mortality
Study or subgroup Vit A with micronutrients micronutrients without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kumwenda 2002 12/285 20/309 100.0 % 0.65 [ 0.32, 1.31 ]
Total (95% CI) 285 309 100.0 % 0.65 [ 0.32, 1.31 ]
Total events: 12 (Vit A with micronutrients), 20 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 3.4. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 4 Stillbirth.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 4 Stillbirth
Study or subgroup Vit A with micronutrients micronutrients without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kumwenda 2002 8/306 6/317 74.6 % 1.38 [ 0.48, 3.93 ]
Muslimatun 2001 3/122 2/121 25.4 % 1.49 [ 0.25, 8.75 ]
Total (95% CI) 428 438 100.0 % 1.41 [ 0.57, 3.47 ]
Total events: 11 (Vit A with micronutrients), 8 (micronutrients without A)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 3.5. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 5 Maternal anaemia.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 5 Maternal anaemia
Study or subgroup Vit A with micronutrients micronutrients without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fawzi 1998 32/226 31/228 32.1 % 1.04 [ 0.66, 1.65 ]
Muslimatun 2001 36/71 44/66 47.4 % 0.76 [ 0.57, 1.01 ]
Semba 2001 18/63 18/52 20.5 % 0.83 [ 0.48, 1.42 ]
Total (95% CI) 360 346 100.0 % 0.86 [ 0.68, 1.09 ]
Total events: 86 (Vit A with micronutrients), 93 (micronutrients without A)
Heterogeneity: Chi2 = 1.43, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 3.8. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 8 Preterm birth.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 8 Preterm birth
Study or subgroup Vit A with micronutrients micronutrients without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dijkhuizen 2004 2/69 5/67 100.0 % 0.39 [ 0.08, 1.93 ]
Total (95% CI) 69 67 100.0 % 0.39 [ 0.08, 1.93 ]
Total events: 2 (Vit A with micronutrients), 5 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 3.9. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 9 Neonatal anaemia.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 9 Neonatal anaemia
Study or subgroup Vit A with micronutrients micronutrients without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Fawzi 1998 185/219 182/211 51.4 % 0.98 [ 0.91, 1.06 ]
Kumwenda 2002 69/297 132/325 48.6 % 0.57 [ 0.45, 0.73 ]
Total (95% CI) 516 536 100.0 % 0.75 [ 0.38, 1.51 ]
Total events: 254 (Vit A with micronutrients), 314 (micronutrients without A)
Heterogeneity: Tau2 = 0.24; Chi2 = 29.31, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.79 (P = 0.43)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 3.12. Comparison 3 Vitamin A with other micronutrients versus micronutrient supplements
without vitamin A, Outcome 12 Low birthweight.
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 3 Vitamin A with other micronutrients versus micronutrient supplements without vitamin A
Outcome: 12 Low birthweight
Study or subgroup Vit A with micronutrients micronutrients without A Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kumwenda 2002 40/285 65/309 100.0 % 0.67 [ 0.47, 0.96 ]
Total (95% CI) 285 309 100.0 % 0.67 [ 0.47, 0.96 ]
Total events: 40 (Vit A with micronutrients), 65 (micronutrients without A)
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 4.1. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 1
Maternal mortality (infant mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 1 Maternal mortality (infant mortality level)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Countries with low infant mortality
Green 1931 -1.10866 (1.711246) 1.1 % 0.33 [ 0.01, 9.44 ]
Subtotal (95% CI) 1.1 % 0.33 [ 0.01, 9.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 Countries with high infant mortality
Kirkwood 2010 -0.08338 (0.120335) 61.9 % 0.92 [ 0.73, 1.16 ]
West 1999 -0.51083 (0.221012) 37.0 % 0.60 [ 0.39, 0.93 ]
Subtotal (95% CI) 98.9 % 0.77 [ 0.51, 1.17 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 2.89, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 1.22 (P = 0.22)
0.02 0.1 1 10 50
Favours experimental Favours control
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(. . . Continued)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 100.0 % 0.78 [ 0.55, 1.10 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 3.18, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 1.42 (P = 0.16)
0.02 0.1 1 10 50
Favours experimental Favours control
Analysis 4.2. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 2
Perinatal mortality (infant mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 2 Perinatal mortality (infant mortality level)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low infant mortality
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Countries with high infant mortality
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 4.3. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 3
Maternal mortality (maternal mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 3 Maternal mortality (maternal mortality level)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low maternal mortality
Green 1931 0/275 1/275 0.7 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 0.7 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Countries with high maternal mortality
Kirkwood 2010 138/39601 148/39234 71.4 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.8 % 0.60 [ 0.40, 0.89 ]
Subtotal (95% CI) 54549 46475 99.3 % 0.83 [ 0.68, 1.02 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.071)
Total (95% CI) 54824 46750 100.0 % 0.83 [ 0.68, 1.01 ]
Total events: 191 (Vit A), 192 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 4.4. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 4
Perinatal mortality (maternal mortality level).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 4 Perinatal mortality (maternal mortality level)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low maternal mortality
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Countries with high maternal mortality
Kirkwood 2010 1140/37042 1187/36701 100.0 % 0.95 [ 0.88, 1.03 ]
Subtotal (95% CI) 37042 36701 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 1140 (Vit A), 1187 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 37042 36701 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 1140 (Vit A), 1187 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
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Analysis 4.5. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 5
Maternal mortality (prevalence of vitamin A deficiency).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 5 Maternal mortality (prevalence of vitamin A deficiency)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low prevalence of vitamin A deficiency
Green 1931 0/275 1/275 0.7 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 0.7 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 High prevalence of vitamin A deficiency
Kirkwood 2010 138/39601 148/39234 71.4 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.8 % 0.60 [ 0.40, 0.89 ]
Subtotal (95% CI) 54549 46475 99.3 % 0.83 [ 0.68, 1.02 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.071)
Total (95% CI) 54824 46750 100.0 % 0.83 [ 0.68, 1.01 ]
Total events: 191 (Vit A), 192 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
69Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.6. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 6
Perinatal mortality (prevalence of vitamin A deficiency).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 6 Perinatal mortality (prevalence of vitamin A deficiency)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low prevalence of vitamin A deficiency
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High prevalence of vitamin A deficiency
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 4.7. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 7
Maternal mortality (prevalence of HIV in the general population).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 7 Maternal mortality (prevalence of HIV in the general population)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low HIV prevalence
Green 1931 0/275 1/275 0.7 % 0.33 [ 0.01, 8.15 ]
Kirkwood 2010 138/39601 148/39234 71.4 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.8 % 0.60 [ 0.40, 0.89 ]
Subtotal (95% CI) 54824 46750 100.0 % 0.83 [ 0.68, 1.01 ]
Total events: 191 (Vit A), 192 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.85 (P = 0.064)
2 Countries with high HIV prevalence
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 54824 46750 100.0 % 0.83 [ 0.68, 1.01 ]
Total events: 191 (Vit A), 192 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.85 (P = 0.064)
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Analysis 4.8. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 8
Perinatal mortality (prevalence of HIV in the general population).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 8 Perinatal mortality (prevalence of HIV in the general population)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Countries with low HIV prevalence
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 Countries with high HIV prevalence
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 4.9. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 9
Maternal mortality (dose).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 9 Maternal mortality (dose)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Daily 10,000 IU
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Others
Kirkwood 2010 138/39601 148/39234 72.0 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 28.0 % 0.60 [ 0.40, 0.89 ]
Subtotal (95% CI) 54549 46475 100.0 % 0.83 [ 0.68, 1.02 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.071)
Total (95% CI) 54549 46475 100.0 % 0.83 [ 0.68, 1.02 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.071)
0.01 0.1 1 10 100
Favours experimental Favours control
73Vitamin A supplementation during pregnancy for maternal and newborn outcomes (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.10. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 10
Perinatal mortality (dose).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 10 Perinatal mortality (dose)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Daily 10,000 IU
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Others
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 4.11. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 11
Maternal mortality (regimen).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 11 Maternal mortality (regimen)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Daily
Green 1931 0/275 1/275 0.7 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 0.7 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Weekly
Kirkwood 2010 138/39601 148/39234 71.4 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.8 % 0.60 [ 0.40, 0.89 ]
Subtotal (95% CI) 54549 46475 99.3 % 0.83 [ 0.68, 1.02 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.071)
3 Other regimen
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 54824 46750 100.0 % 0.83 [ 0.68, 1.01 ]
Total events: 191 (Vit A), 192 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 4.12. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 12
Perinatal mortality (regimen).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 12 Perinatal mortality (regimen)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Daily
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Weekly
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
3 Other regimen
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 4.13. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 13
Maternal mortality (duration of intervention).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 13 Maternal mortality (duration of intervention)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 One month or less
Green 1931 0/275 1/275 100.0 % 0.33 [ 0.01, 8.15 ]
Total (95% CI) 275 275 100.0 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 4.15. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 15
Maternal mortality (trimester of pregnancy).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 15 Maternal mortality (trimester of pregnancy)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-pregnancy
Kirkwood 2010 138/39601 148/39234 71.4 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 27.8 % 0.60 [ 0.40, 0.89 ]
Subtotal (95% CI) 54549 46475 99.3 % 0.83 [ 0.68, 1.02 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.071)
2 First trimester
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
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(. . . Continued)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Second trimester
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Third trimester
Green 1931 0/275 1/275 0.7 % 0.33 [ 0.01, 8.15 ]
Subtotal (95% CI) 275 275 0.7 % 0.33 [ 0.01, 8.15 ]
Total events: 0 (Vit A), 1 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
5 Mixed
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 54824 46750 100.0 % 0.83 [ 0.68, 1.01 ]
Total events: 191 (Vit A), 192 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 4.16. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 16
Perinatal mortality (trimester of pregnancy).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 16 Perinatal mortality (trimester of pregnancy)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Pre-pregnancy
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 First trimester
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Second trimester
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Third trimester
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Mixed
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 4.17. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 17
Maternal mortality (randomisation).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 17 Maternal mortality (randomisation)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cluster-randomised
Kirkwood 2010 138/39601 148/39234 72.0 % 0.92 [ 0.73, 1.16 ]
West 1999 53/14948 43/7241 28.0 % 0.60 [ 0.40, 0.89 ]
Subtotal (95% CI) 54549 46475 100.0 % 0.83 [ 0.68, 1.02 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.071)
2 Individual-randomised
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 54549 46475 100.0 % 0.83 [ 0.68, 1.02 ]
Total events: 191 (Vit A), 191 (Placebo or no treatment)
Heterogeneity: Chi2 = 3.41, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.80 (P = 0.071)
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Analysis 4.18. Comparison 4 Vitamin A alone versus placebo or no treatment (subgroups), Outcome 18
Perinatal mortality (randomisation).
Review: Vitamin A supplementation during pregnancy for maternal and newborn outcomes
Comparison: 4 Vitamin A alone versus placebo or no treatment (subgroups)
Outcome: 18 Perinatal mortality (randomisation)
Study or subgroup Vit A Placebo or no treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cluster-randomised
Kirkwood 2010 2117/38283 2083/37893 100.0 % 1.01 [ 0.95, 1.07 ]
Subtotal (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
2 Individual-randomised
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Vit A), 0 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 38283 37893 100.0 % 1.01 [ 0.95, 1.07 ]
Total events: 2117 (Vit A), 2083 (Placebo or no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
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WH A T ’ S N E W
Last assessed as up-to-date: 4 October 2010.
Date Event Description
15 February 2011 Amended Authors of the Kirkwood 2010 trial provided additional information about the loss to follow up
figure for the pregnancy-related mortality analysis, which was 8% and not 44%.
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